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ABSTRACT 
 
Pamela P. Lockyer: Bone Morphogenetic Protein Binding Endothelial Regulator (BMPER) 
Regulates Vascular Inflammatory Responses in Endothelial Cells 
(Under the direction of Xinchun Pi) 
 
Dysfunction of the vascular endothelium results in various cardiovascular, 
circulatory and blood diseases highlighting the importance of endothelial integrity. How 
BMPER mediates signaling events to regulate endothelial cell functions in response to 
vascular injury with the expectation that these functions can be regulated to affect these 
vascular responses in clinically relevant pathophysiological conditions was the goal for these 
studies. 
Aim 1-We crossed ApoE−/− and Bmper+/− and measured the development of 
atherosclerosis in mice fed a high-fat diet. BMPER haploinsufficiency in ApoE−/− mice led to 
a more severe phenotype.  Aim 2-BMPER+/− were used for LPS challenge. LPS-induced 
pulmonary inflammation and injury was reduced in BMPER+/- mice.  
We conclude that BMPER is essential in the maintenance of normal vascular 
homeostasis during chronic inflammation and atherosclerosis.  Furthermore, BMPER plays a 
pivotal role in pulmonary inflammatory response, to provides new therapeutic options against 
septic shock, and broadens our understanding of BMPER’s role in vascular homeostasis. 
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CHAPTER 1: GENERAL INTRODUCTION                                                 
1.1 THE ENDOTHELIUM IS A BIOLOGICALLY ACTIVE ORGAN 
Blood vessels of the circulatory system, including arteries, veins and capillaries, form 
a network that transports nutrients and oxygen to all parts of the body. The endothelium, 
endothelial cells (EC) and their associated extracellular matrix, forms the inner lining of all 
blood vessels and lymphatic vessels in every organ system in the body. It was once believed 
to be an inert membrane whose only function was to provide a selectively permeable barrier 
to regulate the flow of water and nutrients to underlying tissues.  However, a shift in this 
view began in the 1950s and 1960s.  One important observation showed that lymphocytes 
were observed interacting with the endothelial layer surface, indicating the induction of a 
pro-adhesive, pro-coagulant EC phenotype by inflammatory mediators .1–3 Since then, 
numerous studies have demonstrated that ECs have a central role in many physiologic 
processes, including the control of permeability, vascular tone, hemostasis and immune cell 
trafficking.  The endothelium is also a central determinant in the pathophysiology of most if 
not at all diseases, either as a primary determinant of pathophysiology or as a contributory 
factor to collateral damage. These seminal studies brought about a paradigm shift that led to 
the current view of the endothelium as a dynamic paracrine and endocrine organ that plays a 
critical role in secretory, metabolic and immunologic functions. 1,4–7 However, there is a wide 
bench to bedside gap in endothelial cell medicine. One reason is likely due to the 
heterogeneous properties of the endothelium. Indeed, throughout the vascular tree endothelial 
cells show extensive heterogeneity in structure and function, in space and time as well as in 
health and disease. Despite recent studies our understanding of endothelial cell function 
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remains incomplete.  Further studies of the signaling pathways associated with endothelial 
function are therefore critical in order to develop treatments for these vascular-associated 
conditions. 
1.2 ENDOTHELIAL FUNCTION AND DYSFUNCTION 
ECs play a critical role in vascular homeostasis by regulating many physiologic 
processes, such as vascular tone and permeability, proliferation, apoptosis, production and 
secretion of cytokines and vasoactive substances in response to stress and injury.  ECs 
respond to different insults in an effective manner to maintain a healthy environment that is 
antithrombotic, anticoagulant and anti-inflammatory 1–3,8,9 Under physiologic conditions, ECs 
regulate vascular tone, blood pressure, and blood flow through the fine-tuned release of 
vasodilating factors such as nitric oxide and prostacyclins to counterbalance the 
vasoconstriction caused by endothelin and other vasocontrictors.  To maintain an 
anticoagulant milieu, ECs release mediators of the tissue factor pathway and 
thrombomodulin inhibitors to inhibit activation of the procoagulant molecules thrombin, 
factor X and fibrin. 1,4,6,10,11  In addition to these many functions, ECs also regulate vascular 
homeostasis by responding to physical stimuli exerted on the surface of the endothelium.  In 
this context, ECs function as hemodynamic sensors by responding to mechanical stimulation 
in the vessel wall that is produced by cyclic stretch and fluid shear stress to regulate signaling 
and gene expression.  3,9,10  However, when the endothelium fails to carry out any of these 
essential basal functions endothelial activation develops, and if it is not quickly resolved will 
result in endothelial dysfunction.  Endothelial activation involves a phenotypic change of the 
resting ECs that promotes the pathological process such as inflammation, which contributes 
to the development of many diseases such as atherosclerosis, adult respiratory distress 
syndrome (ARDS), acute lung injury (ALI), and septic shock. 6,11,12 
Dynamic changes of permeability in the vessel wall are regulated by ECs and their 
associated extracellular matrix (ECM). The vascular endothelium provides a size selective, 
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semi-permeable barrier between circulating blood and underlying tissue and actively 
participates in blood-tissue exchange of fluid, ions, proteins and cells.  Strict regulation of 
vascular permeability is required for many physiologic processes, including tissue-fluid 
homeostasis, angiogenesis, vessel tone and host defense.13–15  Conversely, dysregulation of 
barrier function leads to endothelial hyperpermeability, a significant pathological event in 
many diseases, including atherosclerosis, ARDS and sepsis.  ECs regulate the continuous 
movement of fluid, small solutes and macromolecules between the blood and underlying 
tissue using the transcellular and paracellular pathways.  Water and small solutes less than 3 
nm in diameter move through interendothelial junctions by way of the paracellular pathway, 
and the transcellular pathway transports larger molecules across the endothelium by 
vesicular-mediated transport.  An important mechanism for transcellular permeability is 
caveolin-dependent transcytosis. Trancytosis is initiated following protein recognition by 
their membrane-receptors that are located in caveolae.  Ligand-receptor binding activates 
caveolar fission; dynamin oligomers form around the caveolar neck and scission occurs when 
dynamin is hydrolyzed by GTP.  The caveolae then move through the cytoplasm.  The t-
SNARE complex on the basolateral membrane mediates docking and fusion followed by 
exocytosis and release of the vesicular contents into the interstisial space.13,15–17  Paracellular 
permeability is regulated by the dynamic opening closing of EC interendothelial junctions 
(IEJ).  The IEJ complexes are formed by adherens junctions (AJ) and tight junctions (TJ). 
TJs contain claudin, occluding and junctional adhesion molecules.  The transmembrane 
protein, VE-cadherin provides the molecular architecture of AJs.  The extracellular portion of 
VE-cadherin tethers to VE-cadherin on adjacent cells, and members of the catenin family 
link the intracellular domain to the cytoskeleton.  Paracellular permeability is then regulated 
through various mechanisms that cause phosphorylation, internalization, or degradation of 
the junctional proteins.14–16,18 
Blood vessels are constantly subjected to various types of hemodynamic forces such 
as hydrostatic pressure, cyclic stretch, and fluid shear stress.  Shear stress is the force per unit 
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area created by the tangential force of blood flow on the endothelial surface.   The EC 
response to shear stress plays an important role in maintaining vascular homeostasis.  Shear-
induced mechanotransduction transforms mechanical forces to biochemical responses, 
activates signal transduction and endothelium-dependent gene and protein expression that 
determine endothelial cell phenotype. Steady laminar flow (10-50 dyn/cm2) promotes the 
release of factors from ECs that inhibit coagulation, leukocyte trafficking, and SMC 
proliferation while simultaneously promoting EC survival.  In contrast, a dysfunctional 
endothelial phenotype that promotes atheroma formation is seen in areas of the arterial tree 
that promote disturbed flow e.g. curved regions, branch points and bifurcations.4,11,19–24    
Endothelial dysfunction is a failure to perform any of the aforementioned 
physiological functions.  The dysfunctional endothelium becomes pro-adhesive by 
expressing adhesion molecules on the surface, pro-thrombotic by activating circulating 
platelets and leukocytes, and pro-inflammatory by activating NFB, NFAT and other 
signaling pathways. The dysfunctional endothelium is associated with a diverse assortment of 
disorders and diseases including Alzheimer’s disease and neurological conditions associated 
with breakdown of the blood brain barrier, renal diseases, immune deficiencies, infections 
and of course many cardiovascular conditions.  5,11,20,22,25–27 
1.3 ROLE OF ENDOTHELIAL CELLS IN VASCULAR 
INFLAMMATION  
1.3.1 INFLAMMATION 
Inflammation, an integral part of the innate and adaptive immune system, is an 
important first-line of defense against infection, toxins and tissue injury.   ECs are key 
regulators of the inflammatory process.  They orchestrate complex interactions to generate 
the expression of cytokines, chemokines and adhesion molecules.  These inflammatory 
factors in turn recruit plasma proteins, leukocytes and fluid to the injury site.  ECs have a 
crucial role in the inflammatory process.  Not only are ECs the first cells to come in contact 
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with the blood-born injurious agent, ECs receive and process signals from cytokines, 
chemokines and growth factors such as TNF, IL-1, IL-8, MCP-1 and VEGF at the site of 
injury.  ECs respond to these factors to influence the magnitude and timing of the resulting 
inflammatory response.  ECs provide additional counter-regulatory mechanisms to protect 
the host from unrestrained inflammation and excessive tissue injury by responding to 
extrinsic anti-inflammatory signals of the anti-inflammatory cytokines, TGF-, IL-10 and IL-
1 receptor agonist (IL-1ra).  A better understanding of how ECs respond to external anti-
inflammatory signals and the pathways they use will help develop therapeutic options against 
inflammatory derived diseases.11 
1.3.2  ACUTE INFLAMMATORY RESPONSE.    
The innate immune system is the first line of host defense during injury or infection.  
As a result it plays a pivotal role in the early recognition and activation of the 
proinflammatory response to tissue injury or invading pathogens such as lung inflammation 
during septic shock.  Two distinct types of EC activation characterize acute inflammation.  
Type I EC activation lasts for 10-20 minutes and uses G-protein-coupled receptors (GPCRs) 
to transduce several different intracellular signaling pathways that result in increased blood 
flow, vascular leakiness and neutrophil recruitment to the injury site.  Type II endothelial 
activation provides a sustained response that can last hours or days and involves a change in 
gene expression in the injured ECs. 11,22 
To initiate the inflammatory response, innate immune cells recognize pathogen 
invasion or cell damage with either intracellular or surface-expressed pattern recognition 
receptors (PRRs).   Pathogen-associated molecular patterns (PAMPs) are conserved 
structures on pathogens such as microbial nucleic acids, lipoproteins or carbohydrates that 
are recognized by PRRs.  ECs are the first cells to interact with exogenous pathogens, and 
ECs are known to express toll-like receptors, a class of PRRs, on their surface.  Recognition 
of PAMPs by TLRs on ECs activates expression of pro-inflammatory factors through the 
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initiation of signal transduction pathways that lead to the activation of mitogen-activated 
protein (MAP) kinase proteins and NF-B.  This then characterizes ECs both initiators and 
targets of the innate immune response. 28–32 
1.3.3 TOLL-LIKE RECEPTOR SIGNALING IN ENDOTHELIAL CELLS.   
The Toll-like receptor (TLR) family is one of the most extensively studied PRR 
families that recognize PAMPs. TLRs are highly conserved across species and are 
characterized by an extracellular leucine-rich repeat (LRR) domain that mediates ligand 
binding, and a cytoplasmic IL-1 recepter homology (TIR) domain that serves as a docking 
site for TIR-containing cytoplasmic adaptor proteins.  TLR1 through TLR10 are expressed in 
humans and mice, whereas TLR11 threough TLR13 are only expressed in mice.  TLRs can 
be broadly divided into two major groups.  TLR1, 2, 4, 5, 6 and 11 are cell membrane 
receptors, while TLR3, 7, 8, 9, 10 and 13 are confined to intracellular vesicles. The 
expression of TLRs is cell-type specific, and we know that ECs are a heterogeneous 
population of cells, expressing proteins that are vascular bed-specific.  So for our purposes 
we will only discuss TLR4 signaling as it is widely expressed in ECs and has been most 
extensively studied.   TLR4 is activated by lipopolysaccharide (LPS); LPS is a structural 
component of the outer membrane of Gram-negative bacteria and a classical pro-
inflammatory stimulus in mouse sepsis shock models. 22,29,31,33 
LPS-binding protein (LPB) is the first host protein to interact with LPS in the 
extracellular space.  LBP binds LPS and escorts it to the cell surface by binding CD14, a cell-
surface receptor molecule.  CD14 then transfers LPS to the TLR4/MD-2 receptor complex.  
Upon recognition of LPS, TLR4 recruits downstream signal transduction adaptor proteins.  
Activation of TLR4 leads to an early activation of NF-B (MyD88-dependent) and a late-
phase activation of NF-B (MyD88-independent pathway). 
Most TLR signaling is mediated through the MyD88 pathway, which is primarily 
responsible for regulating the expression of the inflammatory cytokines TNF , IL-6 and IL-
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12 via NF-B activation.  In response to LPS stimulation, MyD88 is recruited to the 
intercellular domain of TLR4.  MyD88 then recruits IRAK4, which in turn binds to IRAK1. 
Auto-phosphorylation and activation of IRAK1 leads to IRAK1 binding TRAF6, an adapter 
protein, that forms a complex with UBC`13 and UEV1a which activates TAK1.  TAK1 then 
activates NF-B, MAPK and PI3 pathways to induce pro-inflammatory gene expression.  
On the other hand, TIR-containing adaptor protein, TRIF, mediates MyD88 
independent signaling that activates the transcription factor IRF3 and late phase NF-kB and 
MAPK activation.  To initiate this pathway the adaptor molecule TRAM is recruited to the 
cytoplasmic domain of TLR4.  TRAM then recruits TRIF and this leads more protein 
recruitment and a multiple protein complex with TRAF6, RIP1, NAP1 and TBK1 as 
members.  TBK1 activates the transcription factor IRF3 and RIP1 mediates late phase NF-kB 
activation, leading to cytokine induction. 6,22,28,29,31,33,34 
1.3.4 NF-KB SIGNALING.   
Induction of adhesion molecules and inflammatory cytokines are cardinal 
characteristics of endothelial activation.  Nuclear factor kappa-light chain-enhancer of 
activated B cells (NF-B) is a critical transcriptional regulator involved in the immune and 
inflammatory responses in many cell types including ECs.  NF-B describes various dimeric 
complexes of the Rel protein family.  In mammals the Rel family has five members, NF-B1 
(p105/p50), NF-B2 (p100/p52), Rel A (65), Rel B and c-Rel.  These NF-B proteins form 
many different homo- and hetero-dimers to regulate different transcriptional programs 
depending on the stimulus and cell type.  Each of the five Rel family members has a Rel 
homology domain (RHD) in the N-terminus that is responsible for dimerization, nuclear 
translocation, DNA binding, and interaction with inhibitor of NF-B (IB).   
In unstimulated cells the IkB family of inhibitor proteins sequester NF-B in the 
cytoplasm.  These IB proteins bind the RHD and mask the C-terminal nuclear localization 
sequence (NLS).  The IB proteins are polyubiquitinated and marked for proteasome 
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degradation by IB kinases that phosphorylate signal-dependent serines.  The NLS is then 
exposed inducing NF-kB to translocate to the nucleus, bind DNA and regulate the expression 
of target genes.  
NF-B is activated by a wide range of agonists, such as microbial and viral 
pathogens, LPS, cytokines, low-density lipoprotein (LDL), very low-density lipoprotein 
(VLDL), angiotensin II (ANGII), glucose and disturbed flow.  The pathogenesis of chronic 
inflammation and autoimmune disorders are often preceded by inappropriate NF-
signaling. 
1.3.5 ENDOTHELIAL CELL-DEPENDENT CHRONIC INFLAMMATORY RESPONSE.   
The vascular endothelium is very versatile in nature and can alter its phenotype in 
response to the different phases of the inflammatory process.  The adaptive immune response 
is triggered when innate immunity fails to resolve the injurious stimulus.  The response will 
then progress from acute inflammation to chronic inflammation.  During chronic 
inflammation, ECs modify their expression of adhesion molecules and chemokines; P-
selectin, VCAM1 and ICAM1 are down-regulated, E-selectin is unchanged, and CXC-ligand 
10 (CXCL10) is up-regulated.  This modification promotes the interaction of ECs with type 1 
T helper cells (Th1) that are not present during acute inflammation. 11 
1.4 BMP-BINDING ENDOTHELIAL CELL PRECURSOR-DERIVED 
REGULATOR 
The BMPER gene encodes a 685 amino acid protein and has a molecular mass of 
76.1 kDa.  BMPER contains a 39 amino acid signal peptide followed by five closely spaced 
cysteine-rich von Willebrand factor C (VWC) domains in the N-terminal segment, and the C-
terminal portion has a von Willebrand factor D (VWD) domain and a trypsin inhibitor-like 
(TIL) domain. BMPER was originally identified in a screen for differentially expressed 
protein in developing embryoid bodies and is highly conserved across species.35  The 
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BMPER mouse homolog share 92 percent, zebrafish share 65 percent and drosophila share 
38 percent sequence homology with human BMPER.   
BMPER, through its regulation of the BMP signaling events, is critically involved in 
numerous aspects of EC biology that affect development in the embryo, revascularization in 
adult tissues, and vascular inflammation.  BMPs mediate a diverse range of functions during 
vertebrate development, including left-right embryonic asymmety, neurogenesis, mesoderm 
patterning, organogenesis and cellular differentiation.  BMPER binds BMPs through the first 
VWC domain in the N-terminal region with a 2:1 stochiometry and has both pro-and anti-
BMP activities. 36–38 
BMPER regulates BMP activity in a tissue and stage-dependent manner.  In 
Drosophila the BMPER homolog, Crossveinless 2 (Cv-2), is required for signaling by the 
BMP orthologs, Dpp and Gbb.  Loss of Cv2 in Drosophila results in the failure to form cross 
veins in the wing.  Injection of BMPER mRNA into the Xenopus embryo results in formation 
of a secondary axis due to inhibition of BMP signaling.  In zebrafish zbmper is expressed at 
sites of high BMP activity, while morpholino knockdown of zbmper resulted in a dorsalized 
phenotype, dysmorphic caudal vein plexus, aberrant intersegmental vessel formation and 
reduced numbers of circulating blood cells.   BMPER-/- mutant mice are perinatal lethal and 
embryologic studies reveal BMPER-/- mice have cardiac valve, lung, skeletal, eye and 
kidney developmental defects.  35,39,40 
BMPER has been identified as a novel protective regulator of vascular inflammation 
and vascular diseases.  Previous studies have identified a regulatory role for BMPER in the 
inflammatory response through its regulation of BMP signaling.  BMP4 is well established as 
an inflammatory cytokine, and promotes the inflammatory response in the endothelium.   
BMP4 upregulates the inflammatory molecules ICAM1 and VCAM1 on the surface of the 
endothelium, and BMP4 is induced in atheroprone regions of disturbed blow such as 
branches, bends and bifurcations of the vasculature in vivo.  BMPER and other extracellular 
BMP regulators are upregulated in these regions as well.  Reports also show that BMPER is 
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induced by inflammatory-regulatory stimuli such as oscillatory shear stress and mevastatin, 
and inhibits TNF-induced endothelial inflammation. 35,41–45  
BMPER-dependent signaling responses in the endothelium have been characterized 
by us, and others, firmly establishing a role for BMPER in regulating vascular responses to 
stress in physiologic conditions.40,42,43,46–53  Our laboratory has characterized BMPER’s 
involvement in BMP signaling events associated with vascular development and 
revascularization in adult tissue. Our characterization of BMPER-dependent endothelial 
signaling responses have firmly established a role for BMPER in regulating vascular 
responses to stress in physiologic systems.40,42,43,47,54 Currently, mechanistic details of 
BMPERs regulation of the vascular response to injury, and the signaling pathways involved 
is very limited. Our overall goal is to determine how BMPER-mediated signaling events 
contribute to the regulation of endothelial cell functions in response to vascular injury with 
the expectation that these functions can be regulated to affect these vascular responses in 
clinically relevant pathophysiologic conditions. 
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CHAPTER 2: BMPER INHIBITS ENDOTHELIAL EXPRESSION OF 
INFLAMMATORY ADHESION MOLECULES 
2.1 INTRODUCTION 
Atherosclerosis is a disease that results from plaque formation within arteries, 
resulting in arterial hardening and narrowing. It is mediated by a chronic inflammatory 
process characterized by the accumulation of lipids and inflammatory cells (plaque) along the 
inner walls of arteries.1 Although plaque formation is a complex process, endothelial 
inflammation has been identified as one of the critical initiating factors.1 Endothelial 
inflammation can be induced by decreases or disruptions in blood flow, making some regions 
of the vasculature more prone to plaque formation.2,3 For example, arterial regions that are 
exposed to uniform, unidirectional blood flow with high shear stress are protected from 
endothelial inflammation and have a lower incidence of atherosclerotic plaque formation.3,4 
In comparison, atherosclerotic lesions develop predominantly at branches, bends, and 
bifurcations in arteries,5–7 where endothelial cells are exposed to low or disturbed fluid shear 
stress, resulting in low mean and oscillatory shear stress on the endothelial cells. In these 
lesion-prone regions, disturbed or oscillatory shear stress increases expression of bone 
morphogenetic proteins (BMPs) and their antagonists in the vascular endothelium.8,9 In turn, 
BMPs activate an inflammatory response characterized by the expression of adhesion 
molecules, like intracellular adhesion molecule 1 (ICAM1) and vascular cell adhesion 
molecule 1 (VCAM1) on the endothelial surface.9 Despite this, animal studies examining the 
direct role of bone morphogenetic protein (BMP) on vascular inflammation have been 
inconclusive, with some studies reporting a decrease in inflammatory responses and 
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atherosclerotic lesion formation when BMP activity is increased,10 whereas others conclude 
that BMP plays a proinflammatory role.10,11 Although each of these studies support a central 
role for BMP-mediated endothelial inflammation in atherosclerosis, some uncertainty 
remains about the precise contribution of BMP signaling to endothelial inflammation and 
atherosclerosis. BMPs belong to the transforming growth factor-β superfamily and play 
important roles in cellular processes, such as bone formation, proliferation, differentiation, 
motility, vasculogenesis, and angiogenesis (reviewed by Moreno-Miralles12). More 
specifically, BMP4, together with BMP2 and BMP6, demonstrate important roles in 
endothelial differentiation, migration, and angiogenesis.13–16 Previously we identified 
BMPER, a novel extracellular modulator of BMP signaling, which is required for 
hematopoietic and vascular development and hypoxia–induced retinal 
neovascularization.13,14,17 We have also demonstrated that BMPER regulates BMP4 activity 
in a dose-dependent manner.13 Recent reports show that BMPER is induced by 
inflammatory-regulatory stimuli, such as oscillatory shear stress and mevastatin, and inhibits 
tumor necrosis factor-α–induced endothelial inflammation,18,19 suggesting that BMPER acts 
in an anti-inflammatory capacity in endothelial cells by inhibiting BMP activity. This led us 
to question whether BMPER may also inhibit the endothelial inflammation and subsequent 
pathology associated with atherosclerosis. In this study, we used the apolipoprotein E–
deficient (ApoE−/−) mouse atherosclerotic model to study the effects of BMPER 
haploinsufficiency on the development of atherosclerosis. We used BMPER+/− mice instead 
of BMPER−/− mice because BMPER−/− mice die at birth.13 BMPER+/−;ApoE−/− mice fed a 
high-fat (HF) diet displayed an exacerbated inflammatory vascular response compared with 
ApoE−/− mice with the wild-type BMPER gene (BMPER+/+/ApoE−/−). Mechanistically, we 
demonstrate that BMPER exerts protective effects by inhibiting BMP activity. These data 
demonstrate for the first time that BMPER is a novel player in the development of 
atherosclerosis and in fluid shear stress–modulated inflammatory responses in endothelial 
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cells. Taken together, it suggests that BMPER is a novel protective regulator of vascular 
inflammation and vascular diseases, such as atherosclerosis. 
2.2 RESULTS 
2.2.1 BMPER EXPRESSION PROTECTS AGAINST ATHEROSCLEROTIC LESION 
FORMATION AND CALCIFICATION 
Accumulated evidence suggests that BMPER protects endothelial cells from 
inflammation by inhibiting BMP activity.18,19 Therefore, we used the ApoE−/− mouse model, 
in which a HF diet leads to accelerated atherosclerotic lesion formation and arterial 
calcification, to analyze the in vivo effect of reduced BMPER expression on vascular 
inflammation. We crossed wild-type or ApoE−/− mice with mice that had either 1 or 2 
functional BMPER alleles, resulting in 4 genotypes of experimental mice: 
BMPER+/+/ApoE+/+, BMPER+/−/ApoE+/+, BMPER+/+/ApoE−/−, BMPER+/−/ApoE−/−. These 
mice were then fed either a standard chow or HF diet for 20 weeks, and the formation of 
atherosclerotic plaques in the aorta and aortic sinus regions was evaluated by Oil Red O 
staining. ApoE−/− mice that were haploinsufficient for BMPER expression 
(BMPER+/−/ApoE−/−) responded to the HF diet with enhanced plaque formation compared 
with BMPER+/+/ApoE−/− mice (28.35 ± 2.23% versus 17.96 ± 3.00%, P=0.016), as measured 
by en face staining of aortic lesions (including both thoracic and abdominal aorta, Figure 2.1 
A and 2.1B). In addition, cross-sectional analysis of aortic sinus lesions revealed that the 
plaques formed in the BMPER+/−/ApoE−/− mice were larger compared with lesions in 
BMPER+/+/ApoE−/− mice (0.38 ± 0.02% versus 0.29 ± 0.03%, P=0.018), demonstrating a 
protective effect of BMPER expression on the degree of plaque growth (Figure 2.1C and 
2.1D). When lesion calcification was compared between genotypes, BMPER+/−/ApoE−/− mice 
again showed an exacerbated response, with a 120% increase over baseline levels of 
calcification as determined by von Kossa staining, compared with a 68% increase in the 
BMPER+/+/ApoE−/− mice. This equated to an overall increase in total calcification of 1.12 ± 
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0.25% in BMPER+/−/ApoE−/− mice versus 0.37 ± 0.22% in BMPER+/+/ApoE−/− mice (Figure 
2.1E and 2.1F). BMPER+/−/ApoE−/− mice fed the HF diet showed no differences in body 
weight or serum cholesterol levels compared with BMPER+/+/ApoE−/− mice (Figure 2.6 A 
and 2.6 B), indicating that diet induced increases in weight and lipid levels are not 
responsible for the more robust atherosclerotic phenotype in the BMPER+/-/ApoE−/− mice. 
Together, these results indicate that BMPER plays a protective role in plaque formation and 
arterial calcification in an in vivo model of atherosclerosis. 
2.2.2 BMPER EXPRESSION INHIBITS AORTIC INFLAMMATION 
 Several reports have demonstrated a central role for the BMP signaling 
pathway in promoting endothelial inflammatory responses.8,9,18–20 Therefore, we sought to 
determine whether the protective influence of BMPER on the development of atherosclerotic 
lesions is attributable to changes in vascular inflammation. To test this, we measured the 
degree of macrophage infiltration (a common phenotype observed with the onset of 
atherosclerotic plaques) and expression of inflammatory markers in atherosclerotic plaques in 
BMPER+/+/ApoE−/− and BMPER+/−/ApoE−/− mice. Quantitative analysis revealed a more 
robust degree of macrophage infiltration (determined by CD68 expression) in aortas of 
BMPER+/−/ApoE−/− mice compared with BMPER+/+/ApoE−/− mice (0.143 ± 0.016% CD68-
positive area per aortic cross-sectional area versus 0.057 ± 0.013%, respectively) after 20 
weeks of the HF diet (Figure 2.2 A and 2.2 B). BMPER+/−/ApoE−/− mice also exhibited a 
dramatic increase in the expression of 2 inflammatory markers, ICAM1 and VCAM1, in the 
intima associated with aortic lesions, compared with BMPER+/+/ApoE−/− mice after 20 weeks 
of the HF diet (Figure 2.2 C, D, E and F), supporting the notion that BMPER functions as an 
anti-inflammatory mediator. Similar increases in ICAM1 and VCAM1 expression were also 
observed in serum from BMPER+/−/ApoE−/− mice compared with BMPER+/+/ApoE−/− mice 
after 4 weeks of the HF diet (Figure 2.7). We also performed immunostaining with anti-
BMPER and ANTI-BMP4 antibodies to determine whether there is a change in the level of 
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expression of these proteins in response to vascular inflammation induced by HF diet. We 
observed a robust increase in BMPER (Figure 2.8 A) and BMP4 (Figure 2.8 B) levels in 
mice fed a HF diet compared with those fed a control diet. This increase in BMPER and 
BMP4 correlated with the increased expression of ICAM1/VCAM1 and CD68 signals 
(Figure 2.2), further supporting the notion that the modulation of BMP signaling by BMPER 
plays an important role in the inflammatory responses induced by HF diet. Collectively, these 
data demonstrate that BMPER haploinsufficiency leads to phenotypic changes correlative 
with an increased chronic, vascular inflammatory response and likely contributes to the 
aggravated atherosclerotic lesion formation observed in the BMPER+/−/ApoE−/− mice. 
2.2.3 BMPER INHIBITS SHEAR STRESS–DEPENDENT INDUCTION OF INFLAMMATORY 
ADHESION MOLECULES IN THE ENDOTHELIUM 
Aortic lesions develop predominantly in regions that are exposed to low or disturbed 
fluid shear stress, such as the LC of the aorta. Even under normal hemodynamic conditions, 
previous studies demonstrate higher endothelial inflammation in the LC compared with other 
regions of the aorta, such as the GC,3,4 possibly because of the increased expression of BMPs 
in the vascular endothelium of these regions.8 This difference in lesion formation in the GC 
and LC was also observed in the BMPER atherosclerosis model.  Specifically, we observed 
that there was a very significant increase in lesion area in the LC compared with GC of both 
BMPER+/+/ApoE−/− and BMPER+/−/ApoE−/− mice (Figure 2.9). Immunostaining of the cross 
sections of the LC and GC with an antibody specific for BMPER demonstrated a dramatic 
increase of BMPER protein levels in the intima and media of the LC compared with the GC 
in both BMPER+/+ and BMPER+/− mice (Figure 2.10). To quantitatively determine the 
difference of BMPER protein level in the GC and LC, we also performed Western blotting 
with vessel lysates obtained from the GC and LC. We observed significantly more BMPER 
protein located in the LC than GC in both BMPER+/+ and BMPER+/− mice  (Figure 2.10B), 
suggesting that BMPER protein level is modulated by different fluid shear stress. High shear 
stress in the LC decreases BMPER leading to a decrease in lesion size.  Encouraged by these 
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observations, we used this inherent difference in BMPER expression between the LC and GC 
to analyze the effect of reduced BMPER expression on downstream mediators and effectors 
of BMP activation in these regions of mouse aortas. To simplify our experimental setup, we 
only examined mice on the ApoE+/+ background. Endothelial cells located in the LC region 
of aortas of BMPER+/+ mice displayed abundant Smad1, 5, and 8 activation (as detected by 
phosphorylated Smad1, 5, and 8 signals) compared with endothelial cells in the GC region 
(Figure 2.3A), consistent with previous reports. In contrast, BMPER+/− mice exhibited an 
enhanced increase in Smad activation in the LC region in comparison with BMPER+/+ mice; 
but in addition, BMPER+/− mice had clearly detectable Smad activation in the GC region of 
the aortas, consistent with our in vivo data described above indicating that BMPER functions 
as an anti-inflammatory mediator (Figure 2.3B). Expression patterns of both ICAM1 and 
VCAM1 paralleled that of Smad activation (Figure 2.3C–2.3F), demonstrating that BMPER 
inhibits the endothelial response to oscillatory shear stress–mediated induction of endothelial 
inflammatory adhesion molecules, and in the context of atherosclerosis, may directly inhibit 
the endothelial inflammatory response. 
2.2.4 BMPER INHIBITS BMP4-INDUCED INFLAMMATORY GENE EXPRESSION IN 
ENDOTHELIAL CELLS AND PREVENTS FLUID SHEAR STRESS–INDUCED 
INFLAMMATORY RESPONSES 
Our in vivo results clearly support a role for BMPER in suppressing shear stress–
mediated inflammation. To determine the effects of BMPER on inflammation in the 
endothelial cell compartment, we established a cell-based model to determine whether 
BMPER’s ability to attenuate inflammation is BMP4 dependent and is in response to fluid 
shear stress. Treatment of primary HUVECs with BMP4 increased ICAM1 and VCAM1 
expression at both the RNA and protein levels in a time-dependent manner, with peak 
expression occurring at 8 hours post-treatment (Figure 2.4A and 2.4B and data not shown), 
consistent with the previous reports. This robust BMP4-mediated increase in ICAM1 and 
VCAM1 expression was blocked in the presence of exogenous BMPER (Figure 2.4C), 
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demonstrating that BMPER directly antagonizes BMP4-mediated inflammatory signaling. 
Next, we examined the ability of endogenous BMP4 and BMPER to affect the expression of 
inflammatory markers. Given the robust inflammation seen in the normally quiescent GC 
region of the aorta in BMPER+/−/ApoE−/− mice, we hypothesized that reducing endogenous 
BMP4 or BMPER expression in endothelial cells would affect the inflammatory signature of 
the cells even in the absence of exogenous mediators. As expected, BMP4-targeted siRNA 
reduced expression of ICAM1 and VCAM1 in transfected cells, whereas siRNA-mediated 
reduction of endogenous BMPER expression resulted in a significant increase in these same 
inflammatory markers (Figure 2.4D and 2.4E). Collectively, our data demonstrate that the 
anti-inflammatory function of BMPER in endothelial cells is mediated, at least in part, 
through antagonizing BMP activity.  
Given the effect of BMPER gene dosage on endothelial inflammation in vivo (Figure 
2.3) and the in vitro effects of a reduction of BMPER expression on endothelial inflammation 
in the absence of any stimuli (Figure 2.4), we hypothesized that the inflammatory response to 
shear stress in the aorta may be mediated by changes in the levels of BMPER expression. To 
test this hypothesis directly, we subjected HUVECs to conditions that mimic the shear stress 
conditions in the LC and GC aortic regions using either oscillatory stress (±5 dyne cm−2) or 
laminar shear stress (20 dyne cm−2) for 8 hours, respectively. Consistent with our in vivo 
data, endothelial cells subjected to oscillatory shear had a larger inflammatory response (a 
2.33-fold and 4.56-fold increase in ICAM1 and VCAM1 expression, respectively) compared 
with cells subjected to laminar shear, respectively (Figure 2.5A). Interestingly, we also 
observed increases in BMP4 and BMPER expression in oscillatory shear conditions 
compared with laminar shear conditions (Figure 2.5A). Moreover, the protein ratio of BMP4 
to BMPER increased more dramatically in oscillatory shear conditions compared with 
laminar shear conditions (Figure 2.5B). To determine whether the inflammatory response 
observed in our shear stress model is mediated by changes in BMPER protein level, we used 
siRNA-mediated gene silencing of BMPER and compared the extent of inflammatory marker 
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expression with control siRNA-treated cells. In control siRNA-treated cells, we detected 
higher ICAM1 and VCAM1 expression after oscillatory shear was compared with laminar 
shear (Figure2. 5C–2.5E), with similar patterns of BMP4 and BMPER expression as what 
was seen in untreated cells exposed to both modes of shear stress (Figure 2.5A). In BMPER 
siRNA-treated cells, we observed an increased inflammatory response in oscillatory shear 
conditions compared with control siRNA–treated cells (Figure 2.5C–2.5E), consistent with 
the increased inflammation we observed in the LC regions of BMPER+/− aortas (Figure 2.3). 
Additionally, even in the low inflammatory environment (laminar shear stress), reducing 
BMPER expression resulted in 34% and 68% higher expression of ICAM1 and VCAM1, 
respectively, compared with control siRNA– treated cells (Figure 2.5C–2.5E), paralleling our 
observations seen in the GC regions of BMPER+/− aortas (Figure 2.3). Given that laminar 
shear stress promotes endothelial survival and integrity by activating endothelial nitric oxide 
synthase (eNOS) signaling4 and that BMPER regulates eNOS protein expression and activity 
under static conditions,19 we tested whether eNOS is regulated by BMPER under laminar or 
oscillatory shear conditions. Very excitingly, we observed that control siRNA–treated 
endothelial cells subjected to laminar shear stress for 8 hours displayed a robust increase in 
eNOS phosphorylation compared with cells subjected to oscillatory shear stress (Figure 2.5F 
and 2.5G). However, in BMPER siRNA–treated cells, we observed a significant decrease in 
eNOS phosphorylation (Figure 2.5F and 2.5G) after laminar shear compared with the 
control-treated cells. This suggests that the protective effect of BMPER under laminar shear 
conditions might be mediated by increased eNOS activity. The detailed mechanism behind 
this eNOS regulation by BMPER under laminar shear conditions remains to be determined. 
Taken together, these data demonstrate a protective role for BMPER in laminar shear stress 
environments to reduce endothelial inflammation. 
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2.3 DISCUSSION 
In this study, we have identified a previously unrecognized, protective role for 
BMPER in the setting of atherosclerosis. ApoE−/− mice, which develop an atherosclerotic 
phenotype when fed a HF diet, displayed significantly worsened symptoms when they 
carried only 1 phenocopy of the BMPER gene (BMPER+/−;ApoE−/− mice). Not only did the 
decrease in BMPER levels in these mice cause a dramatic increase in lesion size, it also 
resulted in increased arterial calcification and a heightened induction of endothelial 
inflammatory adhesion molecules in the aorta in regions subjected to oscillatory and laminar 
shear stress. Similar results were found in cultured cell studies, solidifying the notion that 
BMPER is a critical regulator of vascular inflammation and broadening our understanding of 
the role that BMPER plays in the myriad events that result from the BMP signaling pathway.  
Previously, our studies revealed the essential roles of BMP and BMPER signaling in 
endothelial cell differentiation, migration, and angiogenesis.13,14,16,17,21,22 With the results 
from the present study, we can now add vascular inflammation to the growing list of BMP 
signaling events that are regulated by BMPER. BMPER+/− mice demonstrated increased 
Smad activation and expression of the inflammatory markers ICAM1 and VCAM1 in the 
endothelium layer of the LC of the aorta, a region known to be predisposed to atherogenic 
activity attributable to the BMP-mediated vascular inflammation brought about by oscillatory 
shear stress effects on endothelial cells (Figure 2.3). In addition, decreased levels of BMPER 
in BMPER+/−/ApoE−/− mice led to an increase in the number of macrophages that were 
recruited and that migrated to the inflamed, atherogenic regions of the aortas (Figure 2.2A 
and 2.2B), supporting the notion that BMPER acts as a protective regulator of vascular 
inflammation. It is worth noting, however, that BMPER may also play a role in maintaining 
general vascular health in addition to its role in inflammatory responses. Our analysis of 
aortas taken from ApoE+/+ mice that were haploinsufficient for BMPER (BMPER+/−/ApoE+/+ 
mice) revealed a significant increase in the area of atherosclerotic lesions in mouse fed a 
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regular diet (Figure 2.1A and 2.1B). This suggests that BMPER may be important in 
maintaining vascular health even under basal conditions, a theory that will require further 
experiments to determine.  
As compelling as these in vivo results are, however, it is important to remember that 
the decrease in BMPER expression in the BMPER+/− mouse is not limited to endothelial 
cells. Because atherosclerosis is a pathological condition that results from the dysfunction of 
multiple cell types and involves different cellular events, it is not possible, from these in vivo 
studies, to localize the protective effect of BMPER to endothelial cells alone. Indeed, 
published reports demonstrate that BMPs enhance smooth muscle cell migration and induce 
proinflammatory factors, such as inducible nitric oxide synthase and tumor necrosis factor in 
macrophages.23,24 The inhibition of BMP activity by specific inhibitors and antagonist 
decreases vascular calcification, suggesting important roles of BMP in vascular calcification, 
as well as early vascular injury. Therefore, it is entirely possible that BMPER, a secreted 
extracellular BMP modulator, may also be able to influence BMP activity not only in 
endothelial cells but in additional cell types such as smooth muscle cells and macrophages. 
Therefore, the contribution of BMPER to protection against atherogenic processes and 
vascular inflammation will need further investigation.  
As mentioned above, a number of published reports have detailed the role of 
BMPER/BMP signaling in various aspects of endothelial cell function.13,14,16,17,21,22 However, 
the ability of BMPER to inhibit endothelial inflammatory responses has not been investigated 
directly. To examine this aspect of endothelial BMP signaling, we cultured HUVECs and 
subjected them to fluid shear stress to induce an inflammatory response similar to what 
occurs within atherogenic areas of the aorta. We found that BMPER inhibits the 
inflammatory response usually elicited from endothelial cells in response to oscillatory shear 
stress (Figures 2.3 and 2.5). This result is consistent with other reports demonstrating that the 
expression of BMPER and other BMP antagonists is increased by oscillatory shear stress 
compared with laminar shear stress.8 Surprisingly, we found that BMPER also exerts an anti-
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inflammatory effect on endothelial cells exposed to laminar shear stress. Laminar shear stress 
promotes endothelial survival and integrity by activating mitogen activated protein kinases, 
such as extracellular-signal regulated kinase/big mitogen-activated protein kinase 1 and 
endothelial NOS signaling.4 Our data demonstrated that BMPER is also involved in 
protecting endothelial cells exposed to laminar shear stress, partly, because of increases in 
the activity of eNOS and decreases ICAM1 and VCAM1 expression (Figure 2.5C and 2.5F) 
that have recently been attributed to BMPER activity in endothelial cells.19 The exact 
molecular mechanism through which BMPER modulates eNOS activity and other signaling 
pathways of laminar shear stress need further investigation. BMPER has been identified as a 
critical regulator of BMP signaling activity, important in both vascular development and in 
hypoxia-induced retinal neovascularization.13,14 Previously, we reported a gradient effect of 
BMPER’s ability to influence BMP signaling, whereby superstoichiometric concentrations of 
BMPER compared with BMP inhibit BMP signaling and substoichiometric concentrations of 
BMPER compared with BMP activate BMP signaling.13 In this study, we observed 61% and 
15% higher BMP4 and BMPER expression in oscillatory shear stress conditions, resulting in 
a significantly lower BMPER to BMP4 ratio compared with laminar shear stress conditions, 
an expression pattern consistent with an anti-inflammatory role for BMPER (Figure 2.5A and 
2.5B). This observation further suggests that the fine-tuning of BMP activity by BMPER is 
essential for modulating BMP-mediated cellular functions. Collectively, the data presented in 
this report demonstrate that the regulation of BMP activity by BMPER is essential for the 
maintenance of normal vascular homeostasis (Figure 2.11) and its disruption increases the 
risk of inflammatory vascular diseases, such as atherosclerosis. 
2.4 MATERIALS AND METHODS 
2.4.1 ANIMALS AND DIETS 
ApoE-/- mice on C57BL/6J background were kindly provided by Dr. Maeda (UNC, 
Chapel Hill, NC). BMPER+/- mice, previously generated in our laboratory on a C57BL/6J 
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genetic background1, were crossed with ApoE-/- mice to generate BMPER+/-/ApoE-/- mice. 
We used the BMPER+/- mice instead of BMPER-/- mice because BMPER-/- mice die at birth. 
All adult mice were fed with the standard chow or a high-fat/highcholesterol diet (Western 
diet) (Harlan Laboratories, Indianapolis, IN) for 20 weeks. Body weight of mice was 
monitored before and after they were fed with different diets. Blood serum was obtained 
every four weeks. All mouse experimental procedures were performed according to the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and 
approved by the Institutional Committee for the Use of Animals in Research.  
2.4.2 LIPID ANALYSIS 
Mice were fasted for 18 hours before blood sampling. Less than 200 μL of blood was 
collected through submandibular bleeding using a lancet. The total cholesterol level was 
measured enzymatically with a commercially available kit (Infinity kits, Thermo Scientific, 
Waltham, MA). 
2.4.3 LESION QUANTIFICATION 
The mice were euthanized and perfusion fixed with 10% buffered formalin via the 
left ventricle for 5 minutes. The lesions located in the aorta and aortic sinuses were analyzed 
using Oil Red O staining. To measure lesions in the aorta, the whole aorta, including the 
ascending arch, thoracic, and abdominal segments, was dissected, gently cleaned of 
adventitial tissue, and stained with Oil Red O (Sigma, St. Louis, MO). The surface lesion 
area was quantified with ImageJ software (Version 1.42q, NIH, Bethesda, MD) and is 
presented as a percentage of the total surface area of the whole aorta. To measure the lesions 
in the aortic sinuses, the heart and proximal aorta were excised, and the apex and lower half 
of the ventricles were removed. The remaining sample was embedded in optimal cutting 
temperature (OCT) compound (Tissue-Tek, Fisher Scientific, Pittsburgh, PA) and frozen on 
dry ice. Starting from the appearance of the aortic valve, serial frozen sections at 5 μm 
thickness were collected until the aortic valves were completely sectioned after the 
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previously described protocol. Twenty sections were stained with eosin and Oil Red O. The 
slides were imaged by light microscopy, and the atherosclerotic lesion area located in aortic 
sinus area was quantified with ImageJ and averaged over a 280 μm region. 
2.4.4 CALCIFICATION QUANTIFICATION 
Deposited calcium in the aorta was detected by staining with von Kossa. The 5 μm 
cryosections of aortic sinus were prepared as described above and subjected to the von Kossa 
staining procedure. The calcification area from each section was quantified as a percentage of 
the total vessel cross-sectional area using ImageJ software.  
2.4.5 ELISA MEASUREMENTS 
Blood samples were drawn from mice after consuming the HF diet or standard chow 
for 4 weeks. Soluble VCAM and soluble ICAM were measured in plasma in triplicate using 
an ELISA method (R&D Systems Minneapolis, MN). 
2.4.6 REAGENTS 
Recombinant human BMP4 and BMPER protein and antibodies recognizing BMPER 
and BMP4 were obtained from R&D Systems. VCAM1 antibodies were obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA) for Western blotting and Chemicon for 
immunofluorescence (Millipore, Billerica, MA). The ICAM1 antibody was purchased from 
Cell Signaling Technology (Danvers, MA) and was used for Western blotting experiments. 
An additional ICAM1 antibody (purchased from Chemicon) was used for 
immunofluorescence experiments. The phosphorylated Smad1, 5, and 8 antibodies were 
purchased from Cell Signaling Technology and used for both Western blotting and 
immunofluorescence experiments. 
2.4.7 CELL CULTURE AND SIRNA TRANSFECTION 
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza and 
cultured in endothelial basal medium (EBM; Lonza, Allendale, NJ) supplemented with 
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hydrocortisone, bovine brain extract, epidermal growth factor, and 2% fetal calf serum. The 
cells from passages 4–8 were used for experiments. The stealth small interfering RNA 
(siRNA) duplexes were obtained from Invitrogen (Grand Island, NY). The siRNAs against 
mouse BMPER are a mixture of the duplexes of 
5ʹGAAUUUCAGCCAGAAGGAAGCAAAU-3ʹ and 5ʹ-
GGAGAGAUGUGGUCCUCUAUCAAUU-3ʹ.  The siRNA against mouse BMP4 is a 
duplex of 5ʹ-GCAUGUCAGGAUUAGCCGAUCGUUA-3ʹ. The control siRNA is the 
Stealth RNAi negative control duplex (Cat. No. 12935-300) and was purchased from 
Invitrogen. The siRNAs were transfected into HUVECs according to the manufacturer’s 
recommended protocol for Nucleofection (Lonza, Walkersville, MD; the HUVEC protocol). 
Briefly, for each sample, 2×105 HUVECs were transfected with 300 pmol siRNA. The 
experiments with BMP4 or BMPER siRNA-transfected HUVECs were performed 1 day or 4 
days later, respectively. The siRNAs resulted in more than 70 percent knockdown of the 
protein levels of BMP4 and BMPER. 
2.4.8 SHEAR STRESS ASSAYS 
HUVECs were post-confluent for 48 hours before the performance of fluid shear 
stress experiment to decrease the background signal. Laminar shear stress assay was 
described previously. Briefly, confluent cells in a 10-cm dish were exposed to shear stress 
using the cone- and plate-flow chamber system for 8 hours at 20 dyne/cm2 for laminar shear 
stress or ± 5 dyne/cm2 for oscillatory shear stress experiments. 
2.4.9 IMMUNOBLOTTING 
Cells were harvested in lysis buffer (1% Triton X-100, 50 mmol/L Tris (pH 7.4), 150 
mmol/L NaCl, 1 mmol/L Na3VO4, and 0.1% protease inhibitor mixture; Sigma) and 
clarified by centrifugation at 16,000 g. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes. 
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2.4.10 IMMUNOFLUORESCENCE 
The aortic arch segments were dissected out and gently cleaned of the adventitia. The 
aortic fragments located at the greater curvature (GC) and lesser curvature (LC) were 
separated and fixed in 3.7% formaldehyde for 10 minutes at room temperature. The aortic 
fragments were sequentially treated with 70% ethanol for 30 minutes and 5% hydrogen 
peroxide in methanol. Then, the segments were washed with water for 5 minutes. For the 
phosphorylated Smad1, 5, and 8 antibody, the samples were soaked in boiling citric acid 
buffer (10 mmol/L; pH, 6.0) for 9 minutes to expose the antigens. Next, the aortic fragments 
or 5 μm cryosections of the aortic root were blocked with 5% heat-inactivated goat serum for 
1 hour and then incubated overnight with primary antibodies against ICAM1, VCAM1, 
CD31, or CD68 diluted in the blocking solution. After 3 washes in tris buffered saline, cells 
were incubated in the dark with a second antibody conjugated with Alexa Fluor 488 or 568 
(Molecular Probes, Eugene, OR) in blocking solution for 90 minutes at 37°C. After 3 washes 
in tris buffered saline, the fragments were counterstained with DAPI for phosphorylated 
Smad1, 5, and 8 staining. The en face images of the endothelial layer and the cross-sectional 
images of the aortic root were visualized by confocal laser scanning microscopy. 
2.4.11 IMMUNOHISTOCHEMISTRY 
The aortic arch segments were dissected out and gently cleaned of the adventitia. The 
aortic fragments located at the greater curvature (GC) and lesser curvature (LC) were 
separated and fixed in 3.7% formaldehyde for 10 minutes at room temperature. After 
incubating tissue in a sucrose gradient, aortic samples were embedded in OCT compound and 
submitted for frozen sectioning. For the anti-BMPER and BMP4 antibody, the samples were 
soaked in boiling citric acid buffer (10 mmol/L, pH 6.0) for 10 minutes to expose the 
antigens. Next, the 5 μm cryosections of the aortic root or aortic arch were blocked with 5% 
heat inactivated rabbit serum for 1 hour and then incubated overnight with primary 
antibodies against BMPER or BMP4 antibodies diluted in the blocking solution. After three 
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washes in TBS, samples were incubated in a second antibody. For BMPER staining, we 
utilized amplification processes including the serial incubation with ABC (Vector Labs, 
Burlingame, CA, USA) and tyramide signal amplification reagent (Waltham, MA, USA) in 
blocking solution for 30 minutes for each at 37 °C. After 3 washes in TBS, the sections 
stained with BMPER and BMP4 antibodies were developed with DAB. The images were 
recorded using the bright field microscopy with 10x and 20x objective lens. 
2.4.12 STATISTICAL ANALYSIS 
Data are shown as the mean ± SE for 3 to 4 separate experiments. Differences were 
analyzed with 2-way ANOVA and post hoc analyses such as Student t-test when needed. 
Values of P ≤ 0.05 were considered statistically significant. 
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Figure 2-1. BMPER haploinsufficiency leads to aggravated atherosclerotic plaque 
formation.  
Mice were fed a high-fat diet (HF) or standard chow (CH) for 20 weeks. The aorta and heart were 
dissected out and stained with Oil Red O. (A) Representative images of the Oil Red O staining of 
aortas. Scale bar, 1.5 mm. (B) The lesions on the surface of each aorta were quantified as a 
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percentage of the total area of the aorta. *P<0.05, compared with mice with the same genotype but 
fed the control diet. #P<0.05, compared with mice fed with the same diet but with the ApoE−/− 
genotype. The numbers below each column are the number of mice used in the experiments. (C) 
Representative images of Oil Red O–stained sections of aortic sinus regions from mice of the 
designated genotype and food groups. Scale bar, 0.2 mm. (D) The lesions in the aortic sinus region 
were quantified as the percentage of the total lumenal area of aortas. *P<0.05, compared with mice 
with the same genotype but fed the control diet, n≥4. There were no detectable lesions formed in the 
aortic sinus regions of ApoE+/+ mice. (E) Representative images of calcification in the aortas and 
lesions as determined with Von Kossa staining (purple; indicated by black arrows). Scale bar, 0.2 
mm. (F) The area containing calcification deposition was measured as a percentage of the total 
lumenal cross-sectional area of aortas. *P<0.05, compared with mice fed the same diet but with the 
ApoE−/− genotype, n≥5. No detectable calcification detected in aortas of ApoE+/+ mice. 
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Figure 2-2. BMPER haploinsufficiency increases macrophage infiltration and intimal 
inflammation in ApoE−/− mice. 
Representative images showing the CD68-labeled macrophages infiltrate in atherosclerotic lesions of 
mice of the designated genotype and food group. Scale bars, 100 μm. (B) Macrophage infiltration was 
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quantified by measuring the area of CD68-positive cells and calculating this as a percentage of the 
total vessel area of aorta studied. *P<0.05, compared with mice of the same genotype but fed the 
control diet. n=3. (C–F) Intracellular adhesion molecule 1 (ICAM1) (green in C) and vascular cell 
adhesion molecule 1 (VCAM1) (green in E) immunofluorescence in aortic lesions of mice of the 
designated genotype and food group. Shown are representative images of 3 to 5 mice. Scale bars, 25 
μm. Arrows indicate plaques. (D and F) The intimal length containing ICAM1 (C) and VCAM1 (E) 
was measured as a percentage of the total intimal conference. *P<0.05, compared with mice of the 
same genotype but fed the control diet, n≥3. L indicates lumen; M, media.  
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Figure 2-3. BMPER haploinsufficiency results in increased BMP activity and 
expression of inflammatory adhesion molecules in the ApoE+/+ endothelium of the 
greater curvature (GC) and lesser curvature (LC) of the aortic arch. 
(A) En face staining of the GC and LC in the aortic arch of BMPER+/- and BMPER+/- mice was 
performed using an antibody specific for phosphorylated Smad (pSmad) 1, 5, and 8 (green). Nuclei 
were counterstained with DAPI (blue). Arrows indicate pSmad positive nuclei. Scale bar, 10 μm. (B) 
pSmad positive nuclei were quantified as a percentage of all nuclei per field. *P<0.05 compared with 
pSmad positive nuclei (%) in the GC region of the same mice; #P<0.05 compared with pSmad 
positive nuclei (%) in the same region of wild-type littermates, n=3. (C–F) En face staining was 
performed for intracellular adhesion molecule 1 (ICAM1) (green in C) and vascular cell adhesion 
molecule 1 (VCAM1) (green in E) and the endothelial marker CD31 (red in C and E). Scale bar, 10 
μm. (D and F) the average intensity of ICAM1 (D) and VCAM1 (F) was measured as fold change 
over the level of intensity in the GC of wild-type mice. *P<0.05 compared with the relative 
expression level in the GC of the same mice; #P<0.05 compared with the relative expression level in 
the same region of wild-type littermates, n=3. 
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Figure 2-4. BMPER inhibits BMP4– induced ICAM1 and VCAM1 expression. 
Human umbilical vein endothelial cells (HUVECs) were treated with 4 nmol/L of BMP4 for different 
time periods as indicated and then cell lysates were subjected to Western blotting with specific 
antibodies against ICAM1 and VCAM1. (B) ICAM1 and VCAM1 band intensity was quantified with 
ImageJ and normalized against the actin level. *P<0.05 compared with the sample without BMP4 
treatment, n=3. (C) HUVECs were treated with 4 nmol/L BMP4 and increasing concentrations of 
BMPER (5, 10, and 20 nmol/L) for 8 hours. Cell lysates were then subjected to Western blotting with 
specific antibodies against ICAM1 and VCAM1. (D) HUVECs were transfected with BMP4 small 
interfering RNA (siRNA) or control siRNA. Cells were harvested 18 hours later and subjected to 
Western blotting. (E) HUVECs were transfected with BMPER siRNAs or control siRNA. Cells were 
harvested after 96 hours and subjected to Western blotting. 
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A) Human umbilical vein endothelial cells (HUVECs) were subjected to oscillatory shear stress (OS, 
± 5 dyn/cm2) or laminar shear stress (LS, 20 dyn/cm2) or remained static in the incubator for 8 hours. 
Cell lysates were used for immun0-blotting to detect the expression of BMPER and BMP4 and the 
induction of inflammatory adhesion molecules ICAM1 and VCAM1. (B) The band intensity of 
BMP4 and BMPER (A) was quantified with ImageJ and is presented as the ratio of BMP4/BMPER 
protein level compared with the LS condition. *P<0.05 compared with the cells exposed to laminar 
shear stress, n=4. C, HUVECs were transfected with BMPER or control (small interfering RNAs) 
siRNAs. Four days later, cells were exposed to OS (± 5 dyn/cm2), LS (20 dyn/cm2), or static 
conditions for 8 hours. (D and E) The band intensity of ICAM1 (D) and VCAM1 (E) was quantified 
with ImageJ and is presented as the relative fold change of protein level compared with the LS 
condition. *P<0.05 compared to the cells transfected with control siRNAs, n=3; #P<0.05 compared 
Figure 2-5. BMPER is required for the regulation of ICAM1 and VCAM1 expression by 
fluid shear stress. 
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with the cells exposed to LS, n=3. (F) HUVECs were transfected with BMPER or control siRNAs. 
Four days later, cells were exposed to OS (± 5 dyn/cm2), LS (20 dyn/cm2), or static conditions for 8 
hours. Cell lysates were used for immuno -blotting with phospho–endothelial nitric oxide synthase 
(eNOS) (Ser1177) and eNOS antibodies. (G) The band intensity of phospho-eNOS (Ser1177) (E) was 
quantified with ImageJ and is presented as the relative fold change of protein level compared with the 
total eNOS protein level. *P<0.02 compared with the cells at the static condition; #P<0.03 compared 
with the cells transfected with control siRNA, n=3. 
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Figure 2-6. The changes in body weight and total cholesterol level of BMPER/ApoE 
mice after 20 weeks on standard chow (CH) or high fat diet (HF). 
A. The change in body weight after 20 weeks was calculated and demonstrated as a fold-change of 
body weight at Week 20 over Week 0. The numbers listed below the graph are the number of mice 
used for this experiment. (B) The total serum cholesterol level was measured at week 20. *, P<0.05, 
compared to mice with the same genotype but fed with the control diet. #, P<0.05, compared to mice 
fed with the same diet but with the ApoE-/- genotype. 
  
 37 
 
 
Figure 2-7. sICAM1 and sVCAM1 plasma levels increased in BMPER+/- mice after 4 
weeks consuming the high fat diet. 
Blood was collected, and the protein levels of soluble ICAM1 (A) and VCAM1 (B) were measured at 
2eek 4. n=3. 
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Figure 2-8. BMPER and BMP4 expression was increased in mice fed a high fat diet. 
The cryo-sections of aortic root were stained with anti-BMPER (A) and anti-BMP4 (B) antibodies. 
All the mice were on the ApoE-/- background. Scale bar: 200 μm. 
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Figure 2-9. 9 BMPER haploinsufficiency leads to aggravated atherosclerotic plaque 
formation in aortic arch area. 
Mice were fed a high fat diet (HF) or standard chow (CH) for twenty weeks. The aortas were 
dissected out and stained with Oil Red O. The lesions on the surface of each greater and lesser 
curvature of aorta arch were quantified as a percentage of the total area of GC and LC. *, P<0.002, 
compared to that lesions located in GC of the same mouse. #, P<0.05, compared to BMPER+/+ mice 
fed with the same diet. All the mice were on the ApoE-/- background. 
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Figure 2-10. BMPER protein level was increased in the LC compared to GC. 
(A) The regions of GC and LC located in aortic arch of mouse aortas were processed for staining with 
BMPER antibody. Scale bar, 200 μm. The arrows represent the positive staining of BMPER protein. 
Scale bar: 200 μm. (B) The vessel lysates obtained from the GC and LC region of mice were 
subjected to the immuno-blotting with BMPER antibody. Each sample was obtained from two mice. 
*, P<0.05, compared to the sample of the GC in the same mouse. #, P<0.05, compared to the GC 
region of BMPER+/+ mice. n=3. 
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Figure 2-11. Schematic illustration demonstrating how BMPER exerts protective effects 
in the vasculature by regulating BMP4 signaling. 
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CHAPTER 3: LRP1-DEPENDENT BMPER SIGNALING REGULATES 
LPS-INDUCED ACUTE VASCULAR INFLAMMATION 
3.1 INTRODUCTION 
Sepsis is a common cause of significant morbidity and mortality worldwide.  It is the 
tenth leading cause of overall death in the United States, and the incidence of sepsis is 
750,000 and costs $17 billion dollars annually creating a major healthcare burden.25–27 
Despite being one of the oldest clinical syndromes in medicine, there is no specific or 
targeted therapy and the number of patients has continued to increase by 9% each year over 
the past two decades.25 Treatment has been constrained to the useage of antibiotics and 
supportive care.  This underscores the fact that fundamental gaps remain in our knowledge of 
the pathiophysiological mechanisms that drive sepsis.  Injury and dysfunction of multiple 
organs are a clinical manifestation of sepsis, with the lung most commonly involved.  Sepsis 
often leads to ALI or its more severe form, ARDS whose distinguishing features are 
impairment of pulmonary vascular integrity and endothelial dysfunction.  The bacterial 
endotoxin, lipopolysaccharide (LPS), is one of the leading contributing factors to ALI in 
sepsis. 
The endothelium is a major target of sepsis, and endothelial dysfunction accounts for 
significant amount of the pathology in sepsis.  In response to LPS in the blood, endothelial 
cells act as the first line of defense by recognizing invading pathogens via pattern recognition 
receptors (PRR) and initiating inflammatory and coagulation cascades. Proinflammatory 
cytokines secreted from endothelial cells further activate neutrophils, monocytes, tissue 
macrophages and/or endothelial cells. Endothelial cell activation induced by LPS will 
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eventually result in increased vascular permeability, allowing increased flux of proteins, fluid 
and immune cells across vessels into tissues. However, the underlying mechanisms 
mediating endothelial activation in response to LPS remain largely unknown.  
Toll-like receptor 4 (TLR4) has been recognized as the major receptor for LPS. 
Ligation of LPS to TLR4 activates NFκB and nuclear factor of activated T cells (NFAT) 
pathways. In human umbilical vein endothelial cells (HUVECs), TLR4, MyD88 and 
Mal/TIRAP adaptor proteins are required for the activation of NFκB and production of 
interleukin-6 (IL-6).28 Animal studies with inactive NFκB signaling indicate that, in response 
to LPS-induced endotoxemia, NFκB activation acts as a quick adaptive response, which 
provides an important survival signal and maintains a normal but dynamic endothelial barrier 
function.29 On the other hand, LPS activates transcriptional factor NFAT in endothelial cells, 
which results in increased expression of pro-inflammatory cytokines such as IFN-γ and 
TNFα.30 The activation of NFAT is mediated by reactive oxygen species (ROS)-driven Ca2+ 
signaling pathway and TLR4 may be required for ROS generation.30 In activated immune 
cells such as dendritic cells, CD14 is another receptor of LPS leading to NFAT activation, 
likely through Src-family kinase and phospholipase Cγ2, and Ca2+/calcineurin signaling.31 
In endothelial cells, CD14 has also been suggested to function together with TLR4 to 
mediate LPS-induced E-selectin and IL-6 production.32 Although the exact roles of TLR4 
and CD14 in LPS-mediated NFAT activation and endothelial inflammatory responses remain 
to be further clarified, NFAT activation is recognized as a crucial transcription factor 
controlling the expression of pro-inflammatory cytokines. 
Endothelial integrity and vascular homeostasis are tightly regulated by multiple 
signaling pathways such as bone morphogenetic protein (BMP) signaling.33 BMP-binding 
endothelial regulator (BMPER), an extracellular regulator of BMPs,13,21 has been identified 
as an important regulator of vascular inflammation and atherosclerosis.18,19,34 Knockdown of 
BMPER by its specific siRNA or its deficiency in BMPER+/- mice potentiates TNFα 
induced endothelial inflammatory responses.19 This anti-inflammatory phenotype of BMPER 
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is mediated by blocking BMP activity, which likely explains the atheroprotective function of 
BMPER.34 However, it is not clear whether BMPER regulates inflammatory responses in 
endothelial cells in an acute setting, such as LPS challenge. We have recently demonstrated 
that LDLR-related protein (LRP) 1, a member of the LDL receptor family, binds with 
BMPER at the cell membrane, the complex is endocytosed and has been shown to regulate 
angiogenesis during zebrafish vein development.35 The mature form of LRP1 is a 
heterodimer composed of a 515-kDa α chain (LRP1α), possessing four extracellular ligand 
binding domains, and an 85-kDa membrane-anchored cytoplasmic β chain (LRP1β), which 
remains non-covalently associated with α chain. LRP1 is an endocytic receptor for multiple 
signaling pathways and mediates their signals through its β chain, which interacts with many 
scaffolding proteins.36–42 In addition, processed forms of LRP1β can also translocate into 
nucleus and regulate the enzyme activity of PARP143 and expression of PPAR target genes 
by acting as a PPARγ co-activator.44 Although LRP1 is required for the endocytosis of 
BMPER signaling complex in endothelial cells, it remains elusive whether the coupling of 
BMPER to LRP1 may also initiate their own signaling events. 
BMPER null mice die at birth.13 In this study, we used BMPER haploinsufficient 
mice to study the effect of reduced BMPER expression on LPS-induced endothelial 
inflammation. Surprisingly, we observed that BMPER+/- mice exhibit reduced vascular 
inflammatory responses upon LPS treatment as shown by several parameters, including 
endothelial permeability, pulmonary edema, survival rate and production of pro-
inflammatory cytokines. Interestingly, BMPER activates NFATc1 in a LRP1-dependent but 
BMP-independent manner. Furthermore, the coordinative actions of LRP1/NF45 nuclear 
export and NFATc1 nuclear import may play a crucial role for BMPER-induced NFATc1 
activation. These results indicate that inhibition of BMPER signaling limits endotoxemia-
induced pulmonary inflammatory responses and that the BMPER/LRP1 signaling axis may 
provide potential therapeutic targets against sepsis-induced acute lung injury. 
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3.2 RESULTS 
3.2.1 LPS-INDUCED LUNG INJURY AND MORTALITY IS REDUCED IN BMPER+/- MICE 
BMPER has been well characterized in the setting of chronic inflammation and 
atherosclerosis and established as a protective mediator of these processes by inhibiting BMP 
activity in the endothelium.18,19,34 However, it is unknown how BMPER regulates vascular 
responses during acute inflammation. We used a LPS-induced model of endotoxemia and 
BMPER+/- mice (BMPER-/- mice die at birth.13) to investigate the in vivo role of BMPER in 
acute inflammation of the endothelium.  We first challenged BMPER+/- mice and their 
littermate controls (BMPER+/+ mice) with a lethal dose of LPS (15 mg/kg i.v.). We were 
surprised to discover all BMPER+/+ mice died within 2 days while the majority of BMPER+/- 
mice recovered with a 7-day survival rate at approximately 62.5 percent (Figure 3.1A).  Next 
we evaluated histopathological changes in the lungs of BMPER+/- and BMPER+/+ mice 12 
hours after a sub-lethal dose of LPS (10 mg/kg i.v.).  We observed an increased number of 
inflammatory cells in the interstitum and alveolar space, proteinacous debris in the alveolar 
space, interalveolar septal thickening and interstitial edema in BMPER+/+ mice (Figure 3.1B), 
while BMPER+/- mice exhibited much lower instances of these indices of lung injury and had 
a much reduced lung injury score (Figure 3.1C). These data suggest that BMPER 
haploinsufficiency protects against endotoxemia-induced pulmonary injury.   
3.2.2 LPS-INDUCED ENDOTHELIAL PERMEABILITY IS LESS SEVERE IN BMPER 
HAPLOINSUFFICIENT MICE 
To extend our in vivo analysis, we next compared the several lung injury-associated 
parameters of endothelial dysfunction, pulmonary edema and BALF protein concentration.  
When BMPER+/+ control mice were challenged with a sub-lethal dose of LPS (10 mg/kg 
i.v.), they rapidly developed symptoms consistent with sepsis (e.g., lethargy, ocular 
discharge; data not shown), while BMPER haploinsufficient mice (BMPER+/-) demonstrated 
less severe symptoms. Extravasation of Evans blue dye (EBD) from circulation into the lung 
tissue and elevated protein content in the alveolar space are often used as an indicators of 
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elevated capillary permeability. We observed that extravasated EBD content in the lung 
tissue of BMPER+/- mice was significantly less than that from BMPER+/+ mice (Figure 
3.2A,B) as well as total protein collected from broncioalveolar lavage fluid (BALF). 
Similarly the lung wet/dry weight ratio, a measure of pulmonary edema, and the total protein 
concentration in the BALF of BMPER+/- mice, following LPS injection was significantly 
smaller than that of BMPER+/+ mice (Figure 3.2C, D). Taken together, these data suggest that 
BMPER haploinsufficiency protects against pathological endothelial pulmonary 
permeability.   
3.2.3 LPS-INDUCED PRO-INFLAMMATORY CYTOKINE PRODUCTION AND LEUKOCYTE 
MIGRATION ARE ATTENUATED IN BMPER+/- MICE 
Endotoxemia-induced lung inflammation is associated with increases in the 
production of cytokines, both systemically and in the alveolar compartment, and leukocyte 
infiltration into target tissues. Therefore, we evaluated the concentration of LPS-induced pro-
inflammatory cytokines in the serum of BMPER+/+ and BMPER+/- mice. IFNγ, IL-6 and 
TNF-α were induced in BMPER+/+ mice by LPS, while BMPER+/- mice had a significantly 
lower response (Figure 3.3A-C). To further assess the influence of BMPER 
haploinsufficiency on pulmonary inflammation, we determined in the BALF several 
parameters of lung inflammation, including cell infiltration, myeloperoxidase (MPO) activity 
and the levels of IFNγ, IL-6 and TNF-α. In response to LPS, both BMPER+/+ and BMPER+/- 
mice had increased leukocyte infiltration in the BALF, but the cell count in BALF of 
BMPER+/- mice was significantly fewer than those in BMPER+/+ mice (Figure 3.4A).  
Similarly, myeloperoxidase (MPO) activity was also dramatically lower in BMPER+/- mice, 
compared to BMPER+/+ mice (Figure 3.4B) suggesting that BMPER haploinsufficiency 
inhibits leukocyte infiltration into the alveolar space. Next, we measured cytokine levels in 
BALF and found that the individual levels of IFNγ, IL-6 and TNF-α were significantly 
decreased in BMPER+/- mice (Figure 3.3D-F). Taken together, BMPER+/- mice demonstrate a 
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blunted acute pulmonary inflammatory response upon LPS challenge, having reductions in 
leukocyte infiltration and pro-inflammatory cytokine production. 
3.2.4 BMPER REGULATES NFATC1 SIGNALING 
The inhibitory effect of lower gene dosage on LPS-induced lung injury in BMPER 
haploinsufficient mice was unexpected because of the known anti-inflammatory role of 
BMPER in chronic inflammatory responses. The preceeding data suggest BMPER might 
regulate acute and chronic inflammatory responses through distinct pathways. To understand 
the underlying molecular mechanisms responsible for BMPER’s action, we performed gene 
profiling analysis with BMPER treated endothelial cells and searched for changes in gene 
expression. Microarray analysis of endothelial cells treated with BMPER or control revealed 
that BMPER elicits either up-regulation or down-regulation of genes that are not associated 
with BMP transcriptional regulation (Figure 3.5A). To further examine these observations, 
we used TRANSFAC analysis to map transcription factor binding sites upstream of the 
identified BMP-independent BMPER-regulated genes. Interestingly, we found that a number 
of genes regulated by BMPER contain NFAT consensus binding sites including 
phospholipase Cβ1 and NFATc1, which itself is a member of NFAT transcription factors. 
Immunostaining showed the translocation of NFAT to the nucleus after BMPER treatment 
confirming the activation of NFAT by BMPER (Figure 3.5B). There are mainly five 
members of NFAT transcriptional factors that are evolutionarily related to the REL- NFkB 
family of transcription factors: NFAT1 (also known as NFATc2 or NFATp), NFAT2 (also 
known as NFATc1 or NFATc), NFAT3 (also known as NFATc4), NFAT4 (also known as 
NFATc3 or NFATx) and NFAT5 (also known as tonicity enhancer binding protein; 
TonEBP). To examine the relationship between BMPER and NFAT, we assessed the 
induction of NFATs in response to BMPER treatment. By performing real-time PCR 
analysis, we demonstrated that NFATc1 was the most induced NFAT in response to BMPER 
treatment, with the peak at one hour (Figure 3.5C).  
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 BMPER plays a role in LPS signaling pathway in endothelial cells. By using mouse 
lung endothelial cells (MLECs), we investigated whether NFAT, an important transcription 
factor of LPS-induced acute inflammatory responses in endothelial cells,30,31,45,46 can be 
regulated by BMPER. As expected, LPS increased NFAT activity as measured by NFAT 
reporter luciferase activity (Figure 3.6A; data provided by Dr. Hua Mao). However, when 
BMPER expression in MLECs was knocked down with its specific siRNA (Figure 3.6E; data 
provided by Dr. Hua Mao), we observed a ~two-fold decrease in NFAT activation, compared 
to control MLECs (Figure 3.6A; data provided by Dr. Hua Mao). These data suggest that 
BMPER is required for NFAT activation in response to LPS.  Next, we tested whether 
BMPER could activate NFAT by performing the NFAT reporter assay in endothelial cells in 
response to BMPER. When mouse lung endothelial cells were treated with BMPER, we 
observed an increase in NFAT transcriptional activity (Figure 3.6B). NFATc1 must to be 
dephosphorylated then translocate from cytoplasm to the nucleus for activation. We 
performed fractionation assays to determine whether subcellular localization of NFATc1 can 
be regulated by BMPER. Indeed, we observed an increase of NFATc1 accumulation in the 
nucleus after BMPER treatment for 15 to 60 minutes (Figure 3.6C, D). Immunostaining also 
confirmed NFAT nuclear translocation in response to BMPER in endothelial cells (Figure 
3.5B).  Taken together, these data suggest BMPER is not only necessary but also sufficient 
for NFATc1 activation.  
3.2.5 LRP1 MEDIATES NFAT ACTIVATION INDUCED BY BMPER 
To determine how BMPER activates NFATc1, inhibitors of different signaling 
pathways were used to dissect downstream signaling pathways. Importantly, we showed that 
cyclosporin A (CsA; calcineurin inhibitor) and U0126 (MEK1/ERK inhibitor) blocked the 
activation of NFAT upon BMPER treatment (Figure 3.7A).  However, Smad6, which is the 
inhibitor of the BMP’s downstream signaling mediators Smad1, 5 and 8, failed to inhibit 
NFAT activation (Figure 3.7A), suggesting that BMPER activates NFAT through BMP 
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independent pathways. We have recently demonstrated that LRP1 is associated with BMPER 
and is required for BMPER’s regulatory effects on angiogenesis.35 Given that the 
intracellular domain of LRP1β contains multiple serine, threonine and tyrosine residues that 
can be phosphorylated by PKA or Src,42,47 we hypothesized that BMPER may initiate 
signaling cascades directly through LRP1. Treatment with BMPER at increased dosages 
promoted ERK activation. However, ERK activation induced by BMPER was not inhibited 
by BMP4 neutralizing antibody (Figure 3.7B), suggesting that BMPER may induce ERK 
activation in a BMP4-independent manner. On the other hand, LRP1 knockdown 
dramatically decreased ERK activation upon BMPER treatment in MLECs that have been 
transiently transfected with LRP1 siRNA or mouse endothelial cells stably transfected with 
LRP1 shRNA (EC50 is 51.20 nM; Figure 3.7C,D), suggesting that LRP1 is required for 
BMPER-induced ERK activation. Given that ERK pathway is required for BMPER-induced 
NFAT activation, we then tested whether LRP1 is required for NFAT activation. Indeed, 
LRP1 knockdown significantly inhibited NFAT reporter activity in response to BMPER in 
MLECs (Figure 3.7E, **Dr. Hua Mao).  These results suggest that ERK activation mediated 
by LRP1 and calcium dependent calcineurin pathways are required for NFAT activation 
upon BMPER treatment.  
However, many NFAT regulatory elements can also be regulated by NFκB. For 
example, CD28 response element of the IL-2 promoter contains a dimeric NFAT/NFκB site, 
which may bind both NFAT and NFκB and function cooperatively with AP-1 protein that is 
associated with the adjacent AP-1 site.48,49 Therefore, we tested whether BMPER could also 
mediate NFκB signaling. After LPS treatment, we observed a more than two-fold increase in 
IKK activation in BMPER siRNA silenced MLECs, compared to control MLECs (Figure 
3.8A,B). These data suggest that BMPER is required for IKK activation in response to LPS. 
Next, we investigated whether BMPER itself is sufficient to activate IKK and initiate acute 
inflammatory response.  BMPER treatment induces a significant increase in IKK activation 
following 15 and 60 minutes of BMPER treatment (Figure 3.8C,D).  Additionally, NFκB 
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transcriptional activity was increased, determined by NFκB reporter assays (Figure 3.8G). 
However, LRP1 knockdown by its specific siRNA decreased BMPER-induced NFκB 
activity. Taken together, these data suggest that BMPER/LRP1 axis can also activate NFκB 
transcriptional activity. 
3.2.6 NF45 IS ASSOCIATED WITH LRP1Β AND INVOLVED IN NFAT ACTIVATION 
LRP1’s α chain (LRP1α) is responsible for extracellular ligand binding and its β 
chain (LRP1β) for transducing signals. Additionally, LRP1β can be further processed50 and 
translocated to nucleus, where it interacts with nuclear proteins such as poly(ADPribose) 
polymerase-1 (PARP-1)43 and PPARγ44 to regulate cell cycle progression and gene 
transcription. Because we have demonstrated that LRP1 is required for BMPER-induced 
ERK activation (Figure 3.7D), we wanted to determine if the nuclear LRP1β fragment might 
play a role in BMPER-induced NFAT activation. To address this question, we searched for 
LRP1β-interacting proteins as shown in our previous publication.43 First, we performed 
liquid chromatography associated mass spectrometry (LC-MS/MS) analysis to identify 
LRP1β-associated proteins in HEK 293 cells (Figure 3.9A). Nuclear factor 45/interleukin 
binding factor 2 (NF45/ILF2) was among proteins that co-immunoprecipitated with Flag-
LRP1β (Figure 3.9A). NF45 is a nucleic acid-binding protein that regulates cellular gene 
expressions involved in DNA metabolism, transcription, translation, RNA export and 
microRNA biogenesis.51–56 In addition, NF45 is considered as a transcriptional activator of 
IL-2 gene.56 Previous reports show that NF45 and NFAT bind to the same promoter region of 
IL-2 promoter. However, they have different consensus binding sequences (TGTTTAC for 
NF45 and TGGAAAAT for NFAT).57 NF45, unlike NFAT, is associated with the IL-2 
ARRE-2 site even at basal condition.57 To date, it remains unknown whether this 
interchangeable binding of NF45 and NFAT transcriptional complex is important for IL-2 
transcriptional activation. To study the role of NF45 in BMPER-induced gene expression, we 
first confirmed the interaction between overexpressed Flag-LRP1β and NF45 in HEK 293 
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cells (Figure 3.9B). Moreover, their endogenous association was detected in MLECs and 
blocked by the inhibitors of PKA- PKI, Src (PP2) or their combined treatments (Figure 3.9C, 
F), suggesting that the interaction of LRP1β with NF45 requires LRP1β phosphorylation by 
PKA and Src. Furthermore, both immunofluorescence imaging and subcellular fractionation 
analysis demonstrated that LRP1β and its processed intracellular domain, and NF45 were co-
localized mainly in the nucleus of MLECs at basal condition (Figure 3.9D,E). Surprisingly, 
cytosolic levels of NF45, LRP1β and its intracellular domain, but not the processed form of 
LRP1β at 25 kDa, were increased in response to BMPER treatment (Figure 3.9E), suggesting 
that BMPER induces the cytosol translocation of NF45, LRP1β and its intracellular domain, 
but not the LRP1 processing. To further test whether NF45 translocation takes place in LPS-
induced inflammatory setting, we performed immunofluorescent studies in MLECs and lung 
sections. In LPS-treated MLECs, NF45 positive signals in the cytosol fraction were 
significantly increased (Figure 3.10A,B ***Data by Dr. Hua Mao). However, the increased 
signals were blocked in BMPER siRNA transfected MLECs. Additionally, 70.6% of NF45 
signals were localized in cytosol of pulmonary vascular cells in BMPER+/+ mice upon LPS 
injection (Figure 3.10 C,D ***Data by Dr. Hua Mao). However, the cytosol-localized NF45 
signals were decreased to 55.1% in BMPER+/- mice. Together these results indicate that 
NF45 was translocated from the nucleus to cytoplasm in response to LPS and its 
translocation was inhibited by BMPER deficiency, supporting the hypothesis that NF45 
nuclear export is regulated by LPS through a BMPER-dependent pathway. 
Taken together, our results indicate that BMPER acts as a pro-inflammatory stimulus 
during acute lung injury. Its action requires coordination of multiple signaling cascades, 
including the calcium-dependent calcineurin and LRP1-dependent ERK activation pathways, 
the cytosolic translocation of NF45 and nuclear translocation of NFATc1, which eventually 
lead to the activation of NFATc1 and induction of its downstream inflammatory target genes. 
Our studies suggest BMPER signaling is a potential therapeutic target to prevent sepsis-
induced pulmonary inflammation and injury. 
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3.3 DISCUSSION 
The roles of BMPER in inflammation have been examined in several mouse models 
of inflammation including thioglycollate-induced peritonitis and high fat diet induced 
atherosclerosis.19,34 The studies suggest that BMPER plays an anti-inflammatory role through 
modulating BMP activity and thereby blocking TNF-α or oscillatory shear-mediated 
induction of adhesion molecules such as ICAM-1 and VCAM1. In this study, we have 
demonstrated for the first time a pro-inflammatory role of BMPER in LPS-induced acute 
lung injury. BMPER+/- mice exhibit reduced responses upon LPS challenge. Our biochemical 
studies suggest BMPER regulates inflammatory responses through the NFAT pathway, 
which plays important roles in endothelial inflammation. In addition, we provide evidence 
suggesting that BMPER may initiate its own signaling pathways via LRP1, which expands 
our understanding of the roles of BMPER in vascular homeostasis.  
How might BMPER play a pro-inflammatory role in LPS-induced acute lung injury? 
Our gene expression profiling analysis provided us a clue by suggesting that BMPER may 
regulate NFAT transcriptional activity. We then confirmed that BMPER is not only required 
but also sufficient for NFAT activation, which plays an essential role in proinflammatory 
cytokines production in endothelial cells during LPS-induced endotoxemia.30 This BMPER-
induced signaling event involves coordinative actions of multiple pathways.  As we propose 
in the working model (Figure 3.11), BMPER activates ERK pathway in a LRP1-dependent 
manner, which is required for NFAT activation. Although it remains to be further determined 
how calcium/calcineurin signaling is activated by BMPER, the studies with calcineurin 
inhibitor cyclosporine suggest that calcium/calcineurin is also required for BMPER-induced 
NFAT activation. In addition, we discovered that LRP1β is associated with NF45 in the 
nucleus at basal condition. Upon BMPER stimulation, they are translocated to cytoplasm in a 
timely fashion when NFATc1 is translocated to the nucleus. Given that NFATc1 and NF45 
are associated with the same promoter regions of their genes, these observations indicate that 
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NF45 may suppress NFAT transcriptional activity at basal condition. Upon the stimulation, 
the replacement of NF45 by NFAT transcriptional complex could be allowed in a fast 
fashion, which may explain the quick transcriptional events for pro-inflammatory cytokines. 
These timely reactions of endothelial cells, acting as the first line of defense, are essential for 
fighting against septic shock and the resolution of the acute inflammation.  
We, and others, have identified both pro- and anti-BMP activities of BMPER,13,21,58–65 
resulting in some controversy as to whether BMPER is a BMP agonist or antagonist. To 
reconcile this issue, we have extensively analyzed the biochemical events resulting from 
BMPER’s interaction with BMP4 and identified a concentration-dependent switch of 
BMPER from pro- to anti-BMP signaling, which is modulated by the relative concentration 
of BMPER to BMP.35 Specifically, when BMPER is at molar concentrations lower than 
BMP4 (sub-stoichiometric), BMP4 activity is enhanced, leading to increased 
phosphorylation of Smad1/5/8 in mouse endothelial cell. However, when BMPER is at molar 
concentrations higher than BMP4 (supra-stoichiometric), BMP4-mediated Smad1/5/8 
phosphorylation is attenuated. Both the activation and inhibition of BMP4 signaling by 
BMPER require endocytosis of BMPER/BMP4 complex through a clathrin-dependent 
endocytosis pathway, suggesting that endocytosis of BMPER/BMP4 complex is involved in 
BMPER-mediated BMP4 signaling. This provides molecular mechanisms to support a role of 
BMPER in fine tuning BMP signaling at the single cell level. However, it may not 
necessarily explain all the pro- and anti- BMP phenotypes in different animal models. In this 
study, we provide strong evidence suggesting that BMPER, besides acting as an extracellular 
modulator of BMP, may also initiate its own signaling through LRP1 in endothelial cells. 
Even though this adds another layer of complexity to BMPER’s functional roles, it provides 
feasible explanations for BMPER’s different, sometimes even controversial, loss-of-function 
phenotypes in different animal models. 
LPS-induced NFAT pathway plays a pivotal role in vascular endothelial activation. In 
endothelial cells, TLR4, and likely CD14 too, are main receptors of LPS. However, it is 
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unclear whether TLR4 and/or CD14 are required for NFAT activation. In this study, we have 
discovered that BMPER is required and sufficient for NFAT activation. It will be interesting 
to determine how BMPER regulates LPS-induced NFAT activation. LRP1 has been reported 
to transactivate Trk receptors through a Src family kinase-dependent pathway.66 It is likely 
that cross-talk may also exist between LRP1 and TLR4, CD14 and/ or their downstream 
mediators, which coordinately regulate NFAT activation. The detailed protein-protein 
interactions responsible for this cross-talk will become one of our future research directions. 
It is worth noting that the decrease of BMPER expression in the BMPER+/- mouse is 
not limited to endothelial cells. Since BMPER is a secreted protein, it can act on many 
different cell types. Additionally, inflammation is a multi-cellular process that involves not 
only endothelial cells but also other cells such as circulating leukocytes and lung epithelial 
cells. While our investigation has focused on lung endothelial cells, the role of BMPER in 
sepsis or other lung inflammatory pathologies may be more complicated than what we 
observed within this endotoxemia model. Previous studies show that the decreased BMPER 
expression following bleomycin-induced lung injury impairs epithelial barrier function and 
epithelial morphology.67 It is very likely that BMPER haploinsufficiency also regulates 
functions of epithelial cells, neutrophils or other cell types during LPS-induced acute lung 
injury, which remains to be further investigated. Nevertheless, given that BMPER is 
accessible as a secreted protein, our findings shed light that BMPER may become a great 
therapeutic target during endotoxemia, septic shock, and other pulmonary inflammatory 
conditions. 
3.4 MATERIALS AND METHODS 
3.4.1 ANIMALS 
BMPER+/- mice, previously created in our lab, and maintained on a C57BL/6 
background. BMPER+/- and BMPER+/+ were generated from this colony, and male mice aged 
10-12 weeks were used.  Mice were housed in micro-isolator cages under pathogen-free 
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conditions and subjected to 12-hour light/dark cycle.  The Baylor College of Medicine 
Institutional Animal Care and Use Committee approved all animal studies, and all 
experimental procedures were performed according to the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals.   
3.4.2 REAGENTS 
Recombinant BMPER protein was purchased from R&D Systems (Cat.1956-CV; 
Minneapolis, MN). Cyclosporin A (CsA) was purchased from Sigma (Cat. C1832; St. Louis, 
MO) and U0126 was purchased from EMD Millipore (Cat. 19-147; Billerica, MA). The 
Smad6 construct was purchased from Addgene ( Cambridge, MA). The following antibodies 
were used for immunoblotting: LRP1 purchased from Sigma (Cat. L2170; St. Louis, MO), 
NF45 antibody purchaced from Santa Cruz Biotechnology (Cat. Sc-271718; Santa Cruz, 
CA), Lamin B1 and HSP90 purchased from Cell Signaling Technology (cat. 12586, 4877; 
Danvers, MA), and NFATc1 purchased from BD Pharmingen (Cat. 556602; San Jose, CA).  
3.4.3 MODEL OF ENDOTOXEMIA 
Lipopolysaccharide (LPS) from E. coli serotype O111:B4 was purchased from 
Calboichem/EMD Millipore (Cat. 437627-5mg; Billerica, MA) for cellularity, total protein 
and cytokine studies, The LPS was reconstituted in sterile saline (1.0 mg/ml) and mice were 
given 10 mg/kg intravenously (i.v.) via tail vein. Mice were sacrificed 6 hours after LPS 
injection and serum or BALF samples were collected.   
3.4.4 CAPILLARY LEAKAGE-MILES ASSAY 
Evans blue dye (EBD; 1% w/v) was dissolved in PBS and injected into the tail vein of 
mice 12 hours after LPS injection to assess pulmonary capillary permeability. After 30 
minutes, animals were euthanized and their lungs were perfused with 2 ml PBS. The lungs 
were then excised, placed in a 2.0 ml tube in a 60°C heat block for 48 hours. The lung was 
then homogenized in 0.03 ml of formamide per 1 mg of dry tissue, and incubated at 60°C for 
additional 24 hours. The EBD was then extracted by centrifuging lung tissue samples at 
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5,000 x g for 30 minutes. The supernatants were collected and the absorbance was measured 
at 620 and 740nm using a Tecan Infinite® 200 Pro microplate reader. The EBD 
concentration was determined from standard absorbance curves that were measured in 
parallel. To correct for contaminating heme pigments, the following formula was used:  
EBD=E620 – (1.426 x E740 + 0.030). 
3.4.5 LUNG WET/DRY RATIO 
For determination of lung wet/dry ratios, the whole lung was excised, cleaned and 
weighed. The lung was then placed in a 2 ml tube and incubated at 60°C (dry heat) with the 
tube lid open for 48 hours. Then weighed a second time and the wet-to-dry weight calculated. 
 
3.4.6 LUNG HISTOLOGY 
Harvested lungs were fixed in 10% formalin. Tissues were embedded in paraffin. 
Five micrometer-thick sections were stained with H&E and analyzed by light microscopy. 
Lung injury was graded from 1 (normal) to 4 (severe) in four categories: interstitial 
inflammation, neutrophil infiltration, congestion, and edema according to previous 
reports.68,69 The injury score was calculated by adding the individual scores for each 
category. Scoring was performed blindly. Lung tissues were also prepared for frozen 
sectioning. The frozen sections were used for immunofluorescent imaging and NF45 
translocalization studies. 
3.4.7 BAL FLUID COLLECTION 
Bronchoalveolar lavage (BAL) fluid (BALF) was obtained by flushing 3x 0.8 ml 
aliquots of saline into the lung via a tracheal cannula. The pooled BALF was centrifuged at 
500 x g at 4°C for 5 minutes. Cell pellets were then resuspended in 500 μl PBS and the total 
cell number was counted using a hemocytometer. The supernatant of BALF was stored at -
80°C for subsequent analysis of protein content and cytokine ELISAs. 
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3.4.8 SERUM COLLECTION 
Blood was collected from the submandibular vein 6 hours after LPS injection.  
Approximately 400-600 l whole blood was captured in amber serum separator BD 
Microtainer® tubes. Tubes were inverted 5 times, incubated at room temperature 30 minutes, 
centrifuged 10,000xg 5 minutes, serum (top) layer transferred to labeled 1.5ml tube and 
stored at -80°C. 
 
3.4.9 BALF PROTEIN QUANTITATION 
After centrifugation of BALF samples, total protein concentration was determined 
using the Bio-Rad Protein Assay per the manufacturer’s instructions (Cat. 500-0006; 
Hercules, CA).  Qiying Fan, Ph.D, kindly performed this assay. 
 
3.4.10 CYTOKINE MEASUREMENTS 
Serum and BALF levels of TNF-a, IL-6 and IFN-g were measured using ELISA kits 
(R&D Systems, Minneapolis, MN) according to the manufacturer instructions. 
3.4.11 CELL CULTURE AND TRANSIENT TRANSFECTIONS 
Mouse primary lung microvascular endothelial cells (MLECs), purchased from Cell 
Biologics (Chicago, IL), were cultured in MCDB131 basal medium supplemented with 5% 
FBS, VEGF, ECGS, Heparin, EGF, hydrocortisone, L-glutamine and antibiotic solution. 
Cells ranging from passage 6-10 were used for experiments.  Approximately 70% confluent 
cells in 6-well plates were transfected for 3 hours with 1 μg of plasmids using 4 μl of 
Lipofectamine LTX and 4 μl of Plus reagent (Life Technologies) following our previous 
protocol.43 Two days later, cells were treated with indicated reagents for further assays. For 
stably expressed LRP1 in 293 cells, 90-100% confluent 293 cells in 10-cm dishes were 
transfected 24 hours after plating with 2 μg of Flag-tagged LRP1β plasmid using 20 μl of 
Lipofectamine 2000 (Life Technologies) and then transfected cells were selected by using 
Geneticin (G418; Life Technologies). 
 58 
3.4.12 LUCIFERASE ASSAY 
MLECs were transfected with NFAT-responsive or NFκB firefly luciferase and 
constitutively expressing renilla plasmids (Cignal™ Reporter Assay kits from Qiagen, 
Valencia, CA). One day later, cells were treated with BMPER or LPS as indicated. Cells 
were lysed 24 hours later and analyzed with the Dual-Luciferase® Reporter Assay System 
from Promega (Madison, WI) according to the manufacturer’s instructions using a Tecan 
Infinite® 200 Pro microplate reader. 
3.4.13 SUBCELLULAR FRACTIONATION ASSAY 
Subcellular fractions (cytosolic and nuclear) were obtained following previous 
protocol70 with a slight modification. MLECs were lysed using hypotonic buffer, and the 
supernatant (cytosolic) and pellet (nuclear fraction) were separated by centrifugation at 
15,000 x g for 5 minutes. Purity and consistency of fractions were confirmed using 
antibodies against markers for different subcellular compartments: anti-HSP90 (cytosolic 
marker) and anti-Lamin B1 (nuclear marker). 
3.4.14 SIRNA DESIGN AND TRANSIENT TRANSFECTION 
The stealth siRNA duplexes were obtained from Life Technologies. The siRNA 
against mouse LRP1 is a duplex of 5'-CCAAGGUGUGAGGUGAACAAGUGUA -3'. The 
siRNAs of mouse NFATc1 (Cat. No. MSS275980), NF45 (Cat. No. MSS228688) and 
control siRNA (stealth RNAi negative control duplex; Cat. No. 12935-300) were purchased 
from Life Technologies. The siRNAs were transfected into MLECs according to our 
previous published protocol.43 Briefly, for each sample, 2x105 MLECs were transfected with 
100 pmol siRNA. The experiments with siRNA transfected MLECs were performed two 
days later. 
3.4.15 REAL-TIME PCR 
Total RNAs were reverse transcribed into cDNAs with iScriptTM cDNA synthesis kit 
(Bio- Rad, Hercules, CA, USA). The specific pairs of primers used for the real-time PCR are 
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the following: NFATc1 (forward primer: 5'- tccaaagtcattttcgtgga-3' and reverse primer: 5'- 
ctttgcttccatctcccaga 3'), GAPDH (forward primer: 5'- tgtccgtcgtggatctgac-3' and reverse 
primer: 5'-cctgcttcaccaccttcttg- 3'); designed by Universal ProbeLibrary Assay Design Center 
tool (Roche, Indianapolis, IN). The real-time PCR was performed with FastStart Universal 
Probe Master mix and specific primers and probes for each gene (Universal ProbeLibrary 
Single Probes #50 for NFATc1, and #80 for GAPDH) in Roche Lightcycler 480 PCR 
machine. The reaction mixtures were incubated at 95°C for 10 min followed by 55 cycles at 
95°C for 10 sec and 60°C for 30 sec. GAPDH was used as the housekeeping gene. 
3.4.16 IMMUNOBLOTTING AND IMMUNOPRECIPITATION 
Cells were harvested in lysis buffer (1% Triton X-100, 50 mmol/L Tris (pH 7.4), 150 
mmol/L NaCl, 1 mmol/L Na3VO4 and 0.1% protease inhibitor mixture; Sigma) and clarified 
by centrifugation at 15,000 x g. Proteins were separated by SDS-PAGE and transferred onto 
0.45 mm PVDF membranes. Immunoprecipitation experiments were carried out on cell 
lysates of HEK293 cells or MLECs as indicated. Cell lysates were incubated with flag 
(Sigma) or protein A/G plus-agarose beads (Santa Cruz Biotechnology) overnight at 4°C 
with gentle rotation. Immune complexes were then separated by SDS-PAGE and analyzed by 
Western blot.  
3.4.17 IMMUNOFLUORESCENCE AND CO-LOCALIZATION ANALYSIS 
Immunofluorescence with cultured MLECs was performed following our previously 
published protocol.43 Cells were cultured on 2% gelatin coated coverslips and fixed in 3.7% 
paraformaldehyde for 10 min at room temperature. After 3 washes with PBS, cells were 
sequentially treated with 0.2% Triton X-100 for 5 min (to permeabilize), then 5% boiled 
serum for 1 hour (for blocking), then with the primary antibody overnight in the blocking 
solution. After 3 washes, cells were incubated in the dark with secondary antibody 
conjugated with Alexa Fluor® 568 (Life Technologies) in blocking solution for 90 min at 
37°C. After 3 washes in PBS, the slides were mounted and fluorescent signals were imaged 
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via confocal laser scanning microscopy (Zeiss Pascal, Zeiss, Germany). The relative intensity 
of LRP1β and NF45 in whole vessels, nuclear and cytoplasmic fractions of each cell was 
quantified with Image J. 
3.4.18 STATISTICAL ANALYSIS 
Data are shown as the mean ± SEM for 3 to 4 separate experiments. Differences were 
analyzed with Student’s t-test or ANOVA and followed by a post hoc test with a correction 
when needed. Values of P≤0.05 were considered statistically significant.
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Figure 3-1. BMPER haploinsufficiency attenuates LPS-induced lung injury and 
promotes survival. 
A-B, Lung injury, as determined by injury scoring and histological analysis, is less severe in 
BMPER+/- mice versus BMPER+/+ mice.  BMPER+/- or BMPER+/+ mice were injected i.v. with a sub-
lethal dose (10 mg/kg) of LPS and sacrificed 16 hours later.  A, Lung tissues were screened for lung 
injury score. n=9 (BMPER+/+) and n=4 (BMPER+/-). B, Representative photomicrographs of lung 
tissue stained with hematoxylin and eosin after LPS injection.  LPS stimulated infiltration of 
inflammatory cells into the lung interstitum and alveolar space, alveolar wall thickening and intra-
alveolar proteinacious exudation.  C, Survival curves for BMPER+/- and BMPER+/+ mice injected i.v. 
with a lethal dose of LPS (15 mg/kg). P=0.003; n=7~8. Analysis, Student’s unpaired t-test (A) log-
rank test (C).   
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Figure 3-2. BMPER haploinsufficiency attenuates LPS-induced pulmonary vascular 
permeability. 
All measures of LPS-induced capillary leakage (A,B), edema (C) and BALF protein content (D)are 
reduced in BMPER+/- versus BMPER+/+ mice.  BMPER+/- or BMPER+/+ mice were injected with a 
sub-lethal dose (10 mg/kg i.v.) of LPS and 16 hours later given a bolus of Evans Blue dye (EBD; 1% 
w/v).  Mice were sacrificed 30 minutes later.  Representative lung tissues with extravated EBD were 
photographed and shown in (B). *P<0.05, compared with mice injected with saline (A,C) or 
BMPER+/+ mice (D);  #P<0.05 compared with BMPER+/+ mice (A,C).  ).  Analysis, two-way 
ANOVA followed by Fisher’s LSD multiple comparison test (A,C) and unpaired Student’s t-test (D).  
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Figure 3-3. BMPER haploinsufficiency reduces proinflammatory cytokines both 
systemically and in BALF after LPS challenge. 
BMPER+/+ and BMPER+/- mice were treated with LPS (10 mg/kg i.v.) or PBS (A-C), and after 6 
hours indicated cytokine concentrations were measures in sera and BALF extracts (A-F).  *P<0.05, 
compared with same mice injected with PBS (A-C) or BMPER+/+ mice (D-F);  #P<0.05, compared 
with BMPER+/+ mice (A-C).  Analysis, two-way ANOVA followed by Fisher’s LSD multiple 
comparison test (A-C) and unpaired Student’s t-test (D-F). 
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Figure 3-4. LPS-induced migration of leukocytes is reduced in BMPER+/- mice. 
BMPER+/- mice had lower cell numbers (A) and myeloperoxidase activity (B) in BALF extracts 6 
hours after LPS treatment (10 mg/kg i.v.).  *P<0.05, compared with BMPER+/+ mice; n=4~9.  
Analysis, unpaired Student’s t-test.  
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Figure 3-5. BMPER induces NFAT-dependent target genes, including NFATc1. 
A, Hierarchical clustering was performed with microarray data of mouse cardiac-derived endothelial 
cells treated with BMPER at 10nM or control for 4 hours. Fold change relative to common reference 
is indicated by red and green intensity. Specific clusters of genes containing NFAT-responsive 
elements in their promoters are boxed. B, BMPER increases NFAT translocation from cytoplasm into 
nucleus in endothelial cells. Mouse cardiac-derived endothelial cells were treated with 10 nM 
BMPER for 30 minutes. The representative images were taken with confocal microscopy. C, BMPER 
induced NFAT transcriptional factors in endothelial cells. MLECs were treated with 10 nM BMPER 
for indicated time periods. NFATc4 is not detectable. NFATc1 is the most induced isoform of NFAT 
transcriptional factors. * P<0.05; n=3. Analysis, two-way ANOVA followed by Fisher’s LSD 
multiple comparison test. 
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Figure 3-6.  BMPER is required and sufficient to activate NFATc1. 
A, BMPER knockdown blocks NFAT activation in response to LPS (10 μg/ml). MLECs were 
transfected with a mixture of NFAT-responsive firefly luciferase and renilla constructs, and BMPER 
or control siRNA. One day later, cells were treated with LPS and the luciferase activity was measured 
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after another day’s incubation. (B), BMPER increases transcriptional activity of NFAT in MLECs. 
MLECs were transfected with a mixture of NFAT-responsive firefly luciferase and renilla constructs. 
After 24 hours, cells were treated with BMPER or control for another 24 hours and the luciferase 
activity was measured. (C-D), BMPER increases nuclear translocation of NFATc1. MLECs were 
treated with 10 nM BMPER for indicated time periods. Nuclear and cytoplasmic enriched fractions of 
cell lysates were used to determine the translocation of NFATc1. Lamin B1 (nuclear marker) and 
HSP90 (cytosol marker) immunoblotting were used to verify the purity of the fractions. NFATc1 
protein levels in nuclear and cytosol fractions were quantified and shown in (D). * P<0.05, compared 
to cells without LPS (A) or BMPER (B,D) treatment; # P<0.05; n=3~6. Analysis was two-way 
ANOVA followed by Fisher’s LSD multiple comparison test (A) and one-way ANOVA (B, D).  
(***Data for figure (A) provided by Hua Mao, Ph.D.)  
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Figure 3-7. LRP1 is required for BMPER induced NFAT activation. 
A, Inhibitors of calcineurin and ERK pathways block NFAT activation upon BMPER treatment. 
MLECs were transfected with constructs of NFAT-responsive luciferase, renilla and inhibitory Smad-
Smad6. After 24 hours, cells were pre-treated with cyclosporine A (CsA), U0126 for half an hour and 
then treated with BMPER or control. Luciferase activity was measured after another day’s incubation. 
B, BMPER-induced ERK activation is not inhibited by BMP4 neutralizing antibody in MECs. Mouse 
cardiac-derived endothelial cells were treated with BMPER at indicated doses for 30 minutes. BMP4 
neutralizing antibody (Nab; 40 ng/ml) was used to pretreat cells to block BMP4 activity. C, BMPER 
increases LRP1-dependent ERK activation. MECs stably transfected with LRP1 shRNA or control 
shRNA were treated with BMPER at different doses for 30 minutes, and then harvested for Western 
blotting. ERK activity was calculated by measuring the intensity of phosphor-ERK and total ERK 
blots, and the value of ERK activity for samples with BMPER treatment at 50 nM was considered 
100% for the calculation of EC50 value. D, BMPER increases LRP1-dependent ERK activation. 
MLECs transiently transfected with LRP1 siRNA were treated with BMPER at 10 nM for 30 
minutes, and then harvested for Western blotting. ERK activity was calculated by measuring the 
intensity of phosphor-ERK and total ERK blots. E, LRP1 is required for NFAT activation induced by 
BMPER. MLECs were transfected with LRP1 or control siRNA, and NFATresponsive luciferase and 
renilla constructs. After 24 hours, cells were treated with BMPER or control. Luciferase activity was 
measured after another day’s incubation. P<0.05, compared to control cells without BMPER or other 
indicated treatments; # P<0.05, compared as indicated (A, B, D) or to control siRNA transfected cells 
upon same treatments; n=3~4. NS, not significant. Analysis, two-way ANOVA followed by Fisher’s 
LSD multiple comparison test. (***Figures D and E, data provided by Hua Mao, Ph.D.) 
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Figure 3-8. BMPER/LRP1 induces NFB activation. 
A, BMPER knockdown blocks IKK phosphorylation in MLECs in response to LPS (10ug/ml) over 
time. B, quantitation of the data in A showing the activation of IKK, as measured by the ratio of the 
phosphorylated IKK to the total IKK. C, BMPER alone induces IKK phosphorylation in MLECs. 
Cells were treated with 10nM BMPER over a period of time and Western blot studies were performed 
with cell lysates. D, is the quantitative data of C showing the activation of IKK, as measured by the 
ratio of the phosphorylated IKK to the total IKK. p<0.05, compared to control. n=3. Analysis was 
one-way ANOVA (B,D), unpaired Student’s t-test (F) and two-way ANOVA followed by Fisher’s 
LSD multiple comparison test (G).  (***Figure 3.8G, Dr. Hua Mao) 
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Figure 3-9. NF45 is associated with LRP1 and involved in NFAT activation. 
A, NF45 is a candidate protein associating with LRP1. Lysates of HEK 293 cells with stably 
transfected Flag-tagged LRP1 β chain (Flag-LRP1β) were immunoprecipitated with an anti-Flag 
antibody and stained with Coomassie blue. Positive bands are subjected to mass spectrometry 
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analysis to identify interacting proteins. NF45 is one of these candidate proteins that are likely 
associated with LRP1. B, Flag-tagged LRP1β is associated with NF45 in HEK293 cells. Lysates of 
HEK 293 cells with stably expressing Flag-LRP1β were immunoprecipitated with an anti-flag resin 
and blotted with an anti- NF45 antibody. C, LRP1β is associated with NF45 in MLECs. Lysates of 
MLECs were immunoprecipitated with anti-LRP1β antibody or control IgG, and analyzed by 
Western blotting with an anti-NF45 antibody. D-E, LRP1β and NF45 are translocated from nucleus to 
cytoplasm upon BMPER treatment. MLECs were treated with BMPER at 10 nM for 15 minutes. 
After fixation, cells were stained with LRP1 (C-terminal) antibody (green), NF45 antibody (red) and 
DAPI (blue) for nucleus and representative pictures were shown in D. LRP1 (C-terminal) antibody 
recognizes both LRP1β and its processed fragments at 25 kDa and 12 kDa intracellular domain. The 
relative intensity of LRP1β and its processed fragments, and NF45 in nuclear and cytoplasmic 
fractions was quantified and the ratios of nuclear to cytoplasmic signals were presented in D. * 
P<0.05, compared to control cells; n=8~12. In addition, MLECs were treated with BMPER and 
fractionation assays was performed. Band intensity of LRP1β, its intracellular domain at 12 kDa 
(LRP1-ICD) and NF45 was calculated and normalized to the sample without BMPER treatment. The 
graph in E shows a decrease in nuclear NF45, LRP1β and LRP1-ICD protein levels but an increase in 
cytosolic NF45, LRP1β and LRP1-ICD. The protein level of the LRP1β processed form at 25 kDa 
was not changed in the cytosol in response to BMPER treatment. * P<0.05, compared to cells without 
BMPER treatment; n=3. F, NF45 knockdown promotes NFAT activity. MLECs were transfected 
with a mixture of NFAT-responsive firefly luciferase and renilla constructs, and NF45 or control 
siRNA. One day later, cells were treated with BMPER at 10 nM and the luciferase activity was 
measured after another day’s incubation. G, The interaction of LRP1β with NF45 is phosphorylation-
dependent. MLECs were treated with PKI (10μM), PP2 (1 μM) or both for one hour. Cell lysates 
were immunoprecipitated with anti-LRP1 antibody or IgG as control and then immunoblotted for 
NF45. *P<0.05, compared to cells without BMPER treatment; #P<0.05; n=3. Analysis was Student’s 
t-test (D), one-way ANOVA (E) and two-way ANOVA followed by Fisher’s LSD multiple 
comparison test (F). (***Figures B, C, F and G; data provided by Hua Mao, Ph.D.) 
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Figure 3-10. NF45 is regulated by BMPER/LRP1 signaling. 
A-B, BMPER knockdown blocks NF45 nuclear export upon LPS treatment. MLECs were transfected 
with BMPER or control siRNA. Two days later, cells were treated with 10 μg/ml LPS for 15 minutes. 
Cells were stained with NF45 antibody (red) and DAPI (blue) for nucleus and representative pictures 
were shown in A. The relative intensity of NF45 in nuclear and cytoplasmic fractions was quantified. 
Fractions of cytoplasmic signals were presented in B. * P<0.05, compared to cells without LPS treatment; 
# P<0.05; n=14. C-D, BMPER haploinsufficiency decreases cytosol localization of NF45 in vascular cells of 
lung sections. BMPER+/- or BMPER+/+ control mice were injected with 10 μg/kg LPS and their lungs were 
harvested for histology. Cells were stained with NF45 antibody (green), lectin (red) for vascular cells and DAPI 
(blue) for nucleus. Representative pictures were shown in C. The intensity of NF45 positive signals in each 
vessel and all the vascular cell nuclei was measured. Fractions of cytosol signals were calculated and 
normalized by the number of vascular cells in each vessel. The quantitative data is presented in D. * P<0.05; n= 
3 vessels per mouse section and 3 mice per group. Analysis was two-way ANOVA followed by Fisher’s LSD 
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multiple comparison test (B) and unpaired Student’s t-test (D).  (***Data for figures A-D provided by Dr. Hua 
Mao) 
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Figure 3-11. Schematic illustration showing how BMPER regulates NFATc1 activation 
via coordination of LRP1, ERK, calcineurin and NF45. 
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CHAPTER 4:SUMMARY 
The experiments described herein attempt to characterized the role of BMPER in the 
vascular response to stress and injury by uncovering the BMPER-dependent signaling events 
and their role in pathophysiologic inflammatory conditions such as atherosclerosis and 
sepsis.  Data generated here reveal that 1) BMPER is a novel player in atherosclerosis and 
fluid-shear stress mediated chronic inflammatory responses in endothelial cells, 2) 
mechanistically, BMPER exerts protective effects by inhibiting BMP activity, 3) inhibition 
of BMPER signaling limits endotoxemia-induced acute inflammatory responses in the 
pulmonary endothelium and 4) BMPER regulates acute inflammatory responses through the 
NFATc1 pathway independent of BMP signaling.  Earlier studies have identified essential 
roles for BMPER in endothelial cell differentiation, migration and angiogenesis through 
BMPER’s regulation of BMP signaling.1–6  Our examination of BMPER here identifies a 
novel role for BMPER in mediating both acute and chronic vascular inflammation.  Yet the 
story is not straightforward.  Since its discovery, BMPER has been frought with controversy 
as to whether it promotes or inhibits BMP signaling, and at first glance it may seem there 
results here only further complicate our knowledge of BMPER’s function in the vasculature. 
The first study presented here clearly shows BMPER to have protective anti-
inflammatory effects during chronic inflammation and atherosclerosis, a chronic 
inflammatory disease.  ApoE-/- mice with reduced BMPER expression have smaller 
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atherosclerotic lesions with less calcification.  Also, when subjected to oscillatory shear 
stress, BMPER reduces the expression of the inflammatory adhesion molecules ICAM1 and 
VCAM1 in endothelial cells.  The second study identifies BMPER as a pro-inflammatory 
mediator in the vasculature during acute inflammation and endotoxemia.  Previous mouse 
models of thioglycollate-induced peritonitis and high fat-induced atherosclerosis7–9 suggest 
an anti-inflammatory role for BMPER through mediating BMP-signaling.  We identify, for 
the first time, a BMP-independent role for BMPER to expand our understanding of how 
BMPER regulates vascular homeostasis.  We show that in an acute inflammatory mouse 
model of endotoxemia that BMPER promotes pulmonary endothelial permeability and 
edema, while reduced BMPER expression enhances survival.  We show biochemically that 
BMPER activates NFAT inflammatory signaling through a novel BMP-independent but 
LRP1-dependent pathway. As compelling as our results may be, they warrant further 
investigation.  Both atherosclerosis and sepsis are complex, multifactorial pathologic 
conditions that result from the dysfunction of many cell types, tissues, genetic and 
environmental factors.  Nevertheless, given that BMPER is accessible as a secreted protein, 
our findings shed light that BMPER may become a therapeutic choice during atherosclerosis, 
endotoxemia, sepsis shock, and other inflammatory conditions. 
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